<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81127</article-id><article-id pub-id-type="doi">10.7554/eLife.81127</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-284734"><name><surname>Raad</surname><given-names>Issam I</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-284730"><name><surname>Hachem</surname><given-names>Ray</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287102"><name><surname>Masayuki</surname><given-names>Nigo</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287103"><name><surname>Datoguia</surname><given-names>Tarcila</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-284727"><name><surname>Dagher</surname><given-names>Hiba</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8483-6977</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-284729"><name><surname>Jiang</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287104"><name><surname>Subbiah</surname><given-names>Vivek</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287105"><name><surname>Siddiqui</surname><given-names>Bilal</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287098"><name><surname>Bayle</surname><given-names>Arnaud</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287445"><name><surname>Somer</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287446"><name><surname>Fernández Cruz</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287110"><name><surname>Gorak</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287114"><name><surname>Bhinder</surname><given-names>Arvinder</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287115"><name><surname>Mori</surname><given-names>Nobuyoshi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8815-5135</contrib-id><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287116"><name><surname>Hamerschlak</surname><given-names>Nelson</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287113"><name><surname>Shelanski</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287400"><name><surname>Dragovich</surname><given-names>Tomislav</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287401"><name><surname>Vong Kiat</surname><given-names>Yee Elise</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8870-1391</contrib-id><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287402"><name><surname>Fakhreddine</surname><given-names>Suha</given-names></name><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287403"><name><surname>Pierre</surname><given-names>Abi Hanna</given-names></name><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287404"><name><surname>Chemaly</surname><given-names>Roy F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287405"><name><surname>Mulanovich</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287406"><name><surname>Adachi</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-284732"><name><surname>Borjan</surname><given-names>Jovan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285523"><name><surname>Khawaja</surname><given-names>Fareed</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285518"><name><surname>Granwehr</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285519"><name><surname>John</surname><given-names>Teny</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285520"><name><surname>Yepez</surname><given-names>Eduardo Yepez</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287427"><name><surname>Torres</surname><given-names>Harrys A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287428"><name><surname>Ammakkanavar</surname><given-names>Natraj Reddy</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con30"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287429"><name><surname>Yibirin</surname><given-names>Marcel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con31"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285521"><name><surname>Reyes-Gibby</surname><given-names>Cielito C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4500-6476</contrib-id><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con32"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285524"><name><surname>Pande</surname><given-names>Mala</given-names></name><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con33"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285525"><name><surname>Ali</surname><given-names>Noman</given-names></name><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="fn" rid="con34"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285526"><name><surname>Rojo</surname><given-names>Raniv Dawey</given-names></name><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="con35"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287430"><name><surname>Ali</surname><given-names>Shahnoor M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con36"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287431"><name><surname>Deeba</surname><given-names>Rita E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con37"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287432"><name><surname>Chaftari</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="fn" rid="con38"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287433"><name><surname>Matsuo</surname><given-names>Takahiro</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con39"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287434"><name><surname>Ishikawa</surname><given-names>Kazuhiro</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con40"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287435"><name><surname>Hasegawa</surname><given-names>Ryo</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con41"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287436"><name><surname>Aguado-Noya</surname><given-names>Ramón</given-names></name><xref ref-type="aff" rid="aff21">21</xref><xref ref-type="fn" rid="con42"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287437"><name><surname>García</surname><given-names>Alvaro Garcia</given-names></name><xref ref-type="aff" rid="aff22">22</xref><xref ref-type="fn" rid="con43"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287438"><name><surname>Puchol</surname><given-names>Cristina Traseira</given-names></name><xref ref-type="aff" rid="aff21">21</xref><xref ref-type="fn" rid="con44"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287439"><name><surname>Lee</surname><given-names>Dong Gun</given-names></name><xref ref-type="aff" rid="aff23">23</xref><xref ref-type="fn" rid="con45"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287440"><name><surname>Slavin</surname><given-names>Monica</given-names></name><xref ref-type="aff" rid="aff24">24</xref><xref ref-type="fn" rid="con46"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287441"><name><surname>Teh</surname><given-names>Benjamin</given-names></name><xref ref-type="aff" rid="aff24">24</xref><xref ref-type="fn" rid="con47"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287453"><name><surname>Arias</surname><given-names>Cesar A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con48"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><collab>Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team</collab><xref ref-type="aff" rid="aff25">25</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139880"><name><surname>Kontoyiannis</surname><given-names>Dimitrios P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con49"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-284731"><name><surname>Malek</surname><given-names>Alexandre E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con50"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-283327"><name><surname>Chaftari</surname><given-names>Anne-Marie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8097-8452</contrib-id><email>achaftari@mdanderson.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con51"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03gds6c39</institution-id><institution>Division of Infectious Diseases, McGovern Medical School, The University of Texas Health Science Center at Houston</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Médica Hematologista Hospital Israelita Albert Einstein</institution><addr-line><named-content content-type="city">São Paulo</named-content></addr-line><country>Brazil</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0509zzg37</institution-id><institution>MD Anderson Cancer Network, UT MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040cn9093</institution-id><institution>Department of Hematology Oncology, Community Health Network</institution></institution-wrap><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjwb503</institution-id><institution>Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay</institution></institution-wrap><addr-line><named-content content-type="city">Villejuif</named-content></addr-line><country>France</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/056nm0533</institution-id><institution>Cooper Medical School of Rowan University, Cooper University Health Care</institution></institution-wrap><addr-line><named-content content-type="city">Camden</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e57nb43</institution-id><institution>Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00v47pv90</institution-id><institution>Department of Hematology Oncology, Baptist Health</institution></institution-wrap><addr-line><named-content content-type="city">Jacksonville</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04gqr8882</institution-id><institution>Department of Hematology/Oncology, Ohio Health Marion</institution></institution-wrap><addr-line><named-content content-type="city">Marion</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002wydw38</institution-id><institution>Department of Infectious Diseases, St. Luke's International Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Tokyo</named-content></addr-line><country>Japan</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cqn7d42</institution-id><institution>Banner MD Anderson Cancer Center – North Colorado</institution></institution-wrap><addr-line><named-content content-type="city">Greely</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution>Division of Cancer Medicine, Banner MD Anderson Cancer Center</institution><addr-line><named-content content-type="city">Gilbert</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d59j24</institution-id><institution>Department of Medical Oncology, Tan Tock Seng Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000tqtb97</institution-id><institution>Department of Infectious Diseases, Rafik Hariri University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Beirut</named-content></addr-line><country>Lebanon</country></aff><aff id="aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Gastroenterology, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e57nb43</institution-id><institution>Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e57nb43</institution-id><institution>Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01fpnj063</institution-id><institution>Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research Institute, The Catholic University of Korea</institution></institution-wrap><addr-line><named-content content-type="city">Seoul</named-content></addr-line><country>Republic of Korea</country></aff><aff id="aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02a8bt934</institution-id><institution>Department of Infectious Diseases and National Centre for Infections in Cancer, Peter MacCallum Cancer Centre</institution></institution-wrap><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff><aff id="aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team at The University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Turajlic</surname><given-names>Samra</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>30</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81127</elocation-id><history><date date-type="received" iso-8601-date="2022-06-24"><day>24</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-01-16"><day>16</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-08-26"><day>26</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.25.22279181"/></event></pub-history><permissions><copyright-statement>© 2023, Raad, Hachem et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Raad, Hachem et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81127-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>In this international multicenter study, we aimed to determine the independent risk factors associated with increased 30 day mortality and the impact of cancer and novel treatment modalities in a large group of patients with and without cancer with COVID-19 from multiple countries.</p></sec><sec id="abs2"><title>Methods:</title><p>We retrospectively collected de-identified data on a cohort of patients with and without cancer diagnosed with COVID-19 between January and November 2020 from 16 international centers.</p></sec><sec id="abs3"><title>Results:</title><p>We analyzed 3966 COVID-19 confirmed patients, 1115 with cancer and 2851 without cancer patients. Patients with cancer were more likely to be pancytopenic and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding 2 wk (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin, and procalcitonin) but were less likely to present with clinical symptoms (p≤0.01). By country-adjusted multivariable logistic regression analyses, cancer was not found to be an independent risk factor for 30 day mortality (p=0.18), whereas lymphopenia was independently associated with increased mortality in all patients and in patients with cancer. Older age (≥65y) was the strongest predictor of 30 day mortality in all patients (OR = 4.47, p&lt;0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30 day mortality (OR = 0.64, p=0.036). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30 day mortality rate than those who did not (5.9 vs 17.6%; p=0.03).</p></sec><sec id="abs4"><title>Conclusions:</title><p>Increased 30 day all-cause mortality from COVID-19 was not independently associated with cancer but was independently associated with lymphopenia often observed in hematolgic malignancy. Remdesivir, particularly in patients with cancer receiving low-flow oxygen, can reduce 30 day all-cause mortality.</p></sec><sec id="abs5"><title>Funding:</title><p>National Cancer Institute and National Institutes of Health.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>COVID-19</kwd><kwd>risk factors</kwd><kwd>multicenter study</kwd><kwd>coronavirus</kwd><kwd>cancer patients</kwd><kwd>non-cancer patients</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Raad</surname><given-names>Issam I</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000098</institution-id><institution>NIH Clinical Center</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Raad</surname><given-names>Issam I</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>National Institutes of Health/National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA016672</award-id><principal-award-recipient><name><surname>Chaftari</surname><given-names>Anne-Marie</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Remdesivir is a promising treatment modality to reduce 30 day all-cause mortality.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The COVID-19 pandemic has challenged the health care system worldwide and has spread to more than 200 countries, causing hundreds of millions confirmed cases and several million deaths (<xref ref-type="bibr" rid="bib8">Johns Hopkins Coronavirus Resource Center, 2021</xref>).</p><p>Data from multiple studies have shown consistently that older age and comorbidities such as cardiovascular disease, diabetes mellitus (DM), hypertension, and chronic obstructive pulmonary disease (COPD) have been associated with severe illness and increased mortality (<xref ref-type="bibr" rid="bib31">Zhou et al., 2020</xref>).</p><p>Several studies on COVID-19 mortality suggested that patients with cancer had poor outcomes (<xref ref-type="bibr" rid="bib10">Kuderer et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Rivera et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Albiges et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Robilotti et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Mehta et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Tian et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Lunski et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Sun et al., 2020</xref>). Many of these studies included only patients with cancer and did not have a comparator group of patients without cancer (<xref ref-type="bibr" rid="bib10">Kuderer et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Rivera et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Albiges et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Robilotti et al., 2020</xref>). Other studies compared COVID-19 mortality between patients with and without cancer and found that patients with cancer had worse outcomes (<xref ref-type="bibr" rid="bib15">Mehta et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Tian et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Lunski et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Sun et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Rüthrich et al., 2021</xref>). However, all of these comparative studies included a relatively small number of patients with cancer and were restricted to a particular country, which limits their generalizability to patients with cancer worldwide.</p><p>Given that many of the therapeutic studies on COVID-19 were conducted in patients without cancer and given the poor outcomes of COVID-19 reported in patients with cancer (<xref ref-type="bibr" rid="bib15">Mehta et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Tian et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Lunski et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Sun et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Rüthrich et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Beigel et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Salazar et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Libster et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Janiaud et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Horby et al., 2021</xref>), we aimed to conduct a large multicenter study to compare the impact of these various treatments on the outcome in patients with cancer vs patients without cancer.</p><p>Therefore, given the global spread of the COVID-19 pandemic and the worldwide prevalence of cancer, we undertook this international initiative that included 16 centers from five continents to study and compare the clinical course, risk factors, and treatment modalities impact on outcomes of COVID-19 in patients with cancer vs patients without cancer on a worldwide basis.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study design and participants</title><p>This was a retrospective international multicenter study that included all patients diagnosed with COVID-19 by RT-PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the site or an outside facility between January 4, 2020 and November 15, 2020.</p><p>The study involved 16 centers from 9 countries, 8 centers in the United States and 1 each in Australia, Brazil, France, Japan, Lebanon, Singapore, South Korea, and Spain. Patients were divided into two groups: patients without cancer and those with cancer diagnosed or treated within a year before the diagnosis of COVID-19.</p></sec><sec id="s2-2"><title>Multicenter collaboration and data collection</title><p>The University of Texas MD Anderson Cancer Center was the coordinating center that designed the study, built the electronic case report form, and collected de-identified patient information from all participating centers using the secure Research Electronic Data Capture platform. We reviewed each patient’s electronic hospital record and collected all needed data. This study was approved by the institutional review board at MD Anderson Cancer Center (Protocol# 2020–0437) and the institutional review boards of the collaborating centers. A patient waiver of informed consent was obtained.</p><p>The follow-up period was defined as 30 days after a diagnosis of COVID-19.</p><p>Neutropenia was defined as an absolute neutrophil count &lt;500 cells/mL. Lymphopenia was defined as an absolute lymphocyte count (ALC) &lt;500 cells/mL.</p></sec><sec id="s2-3"><title>Treatment modalities</title><p>For each patient, data were collected on COVID-19 treatments, including antimicrobial therapy and potential antiviral therapy. We evaluated patient’s oxygen requirement: low flow was defined as oxygen supplementation of ≤6 l/min through a nasal cannula or facemask and high flow included all other modalities of oxygen supplementation, including mechanical ventilation.</p></sec><sec id="s2-4"><title>Outcomes measures</title><p>The primary outcome of interest was 30 day mortality. Any death that occurred within 30 days after COVID-19 diagnosis was considered to be COVID-19-related, irrespective of other comorbidities that could have contributed to death. The secondary outcomes included mechanical ventilation, progression to lower respiratory tract infection, co-infection, and hospital readmissions within 30 days after COVID-19 diagnosis.</p></sec><sec id="s2-5"><title>Statistical analysis</title><p>Patient characteristics and outcomes were compared between COVID-19 patients with and without cancer. Categorical variables were compared using χ<sup>2</sup> or Fisher’s exact test, and continuous variables were compared using Wilcoxon rank sum test. Logistic regression model was used to identify the factors that were independently associated with 30 day mortality, and the following factors were included in the analysis in addition to cancer status: patients’ demographic (including country) and clinical characteristics, medical history, and laboratory findings at diagnosis and treatment. First, univariable analysis of each factor was performed, but factors were not considered if more than 40% of the data were missing. Next all the factors with p-values≤0.15 on their univariable analyses were included in a full logistic regression model and then the full model was reduced to the final model by backward elimination procedure so that all the factors remaining in the final model had p-values≤0.05 except cancer and country. Cancer was kept in the final model despite its p-value in order to evaluate its independent impact on mortality. The final model was country-adjusted to account for the treatment differences among the countries. For the above complete cases analysis, only patients with no missing data in any of the variables retained for the final regression model were included in the final model analysis. To investigate the impact of missing data on our primary data analysis, we performed a sensitivity analysis. We first estimated missing values using multiple imputation technique and then performed a similar multivariable analysis based on the imputed datasets. Lastly, the analysis results were compared between the complete-case and multiple imputation analyses. Logistic regression model was also used to identify the independent predictors of mortality among patients with and without cancer, respectively, and similar sensitivity analysis was performed for each group as well. In cancer patients, the mortality rates of four different cancers were estimated and compared: hematological malignancy, lung cancer, and non-lung solid tumors with and without metastasis. χ<sup>2</sup> or Fisher’s exact test was used for comparisons. If a significant result (p&lt;0.05) was detected, pairwise comparisons were performed with α levels adjusted using Holm’s sequential Bonferroni adjustment to control type I error. In addition, the associations between mortality and certain therapeutic agents including remdesivir, steroids, and convalescent plasma, as well as the impact of their treatment timing on mortality, were also evaluated using χ<sup>2</sup> or Fisher’s exact test. All statistical tests were two-sided with a significance level of 0.05, except the pairwise comparisons with the α adjustment. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC, USA).</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>A total of 4015patients diagnosed with COVID-19 by PCR were included in the study. After excluding 18 patients who had missing demographics and 31 patients younger than 18y, we evaluated 3966 COVID-19 patients: 2851 without cancer and 1115 with cancer (see <xref ref-type="fig" rid="fig1">Figure 1</xref> for a consort flow diagram of patient attrition in analyses).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Consort diagram of patient attrition.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81127-fig1-v2.tif"/></fig><sec id="s3-1"><title>Demographics and clinical characteristics of patients with and without cancer</title><p>Patient characteristics are presented in <xref ref-type="table" rid="table1">Table 1</xref>. Compared to patients without cancer, patients with cancer were older (median age, 61 vs 50 y; p&lt;0.0001); more likely to have a smoking history (38 vs 17%; p&lt;0.0001), pulmonary disorder (27 vs 21%; p&lt;0.001), hypertension (49 vs 36%, p&lt;0.0001), DM (27 vs 23%, p=0.01), or corticosteroid use in the 2 wk preceding COVID-19 diagnosis (17 vs 4%, p&lt;0.0001); and less likely to present with clinical symptoms, including cough (46 vs 65%; p&lt;0.0001), fever (45 vs 66%; p&lt;0.0001), and shortness of breath (35 vs 48%; p&lt;0.0001).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Comparing COVID-19 patients with and without cancer.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Characteristic</th><th align="center" valign="middle">Without cancer (n=2851)<break/>N (%)<break/></th><th align="center" valign="middle">With cancer<break/>(n=1115)<break/>N (%)<break/></th><th align="center" valign="bottom">p-value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Demographic and baseline clinical characteristics</bold></td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Age (years), median (range)</td><td align="center" valign="middle">50 (18–100)</td><td align="center" valign="middle">61 (18–100)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Sex, male</td><td align="center" valign="middle">1335 (47)</td><td align="center" valign="middle">506 (45)</td><td align="center" valign="middle">0.41</td></tr><tr><td align="left" valign="bottom">Race/ethnicity</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">White</td><td align="center" valign="middle">720/2674 (27)</td><td align="center" valign="middle">534/916 (58)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Black</td><td align="center" valign="middle">517/2674 (19)</td><td align="center" valign="middle">155/916 (17)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Hispanic</td><td align="center" valign="middle">547/2674 (20)</td><td align="center" valign="middle">178/916 (19)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Asian</td><td align="center" valign="middle">275/2674 (10)</td><td align="center" valign="middle">33/916 (4)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Middle Eastern</td><td align="center" valign="middle">63/2674 (2)</td><td align="center" valign="middle">3/916 (0.3)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Other</td><td align="center" valign="middle">552/2674 (21)</td><td align="center" valign="middle">13/916 (1)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Prior pulmonary disorders</td><td align="center" valign="middle">431/2064 (21)</td><td align="center" valign="middle">275/1017 (27)</td><td align="center" valign="middle">&lt;0.001</td></tr><tr><td align="left" valign="bottom">COPD/bronchiolitis obliterans</td><td align="center" valign="middle">175/2054 (9)</td><td align="center" valign="middle">75 (7)</td><td align="center" valign="middle">0.07</td></tr><tr><td align="left" valign="bottom">Asthma</td><td align="center" valign="middle">178 (6)</td><td align="center" valign="middle">106 (10)</td><td align="center" valign="middle">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Obstructive sleep apnea</td><td align="center" valign="middle">98/2054 (5)</td><td align="center" valign="middle">89/948 (9)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">History of heart failure</td><td align="center" valign="middle">240/2036 (12)</td><td align="center" valign="middle">85/1098 (8)</td><td align="center" valign="middle">&lt;0.001</td></tr><tr><td align="left" valign="bottom">History of ischemic heart disease</td><td align="center" valign="middle">226/2830 (8)</td><td align="center" valign="middle">94/1101 (9)</td><td align="center" valign="middle">0.57</td></tr><tr><td align="left" valign="bottom">History of hypertension</td><td align="center" valign="middle">1020/2837 (36)</td><td align="center" valign="middle">546/1110 (49)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">History of diabetes mellitus</td><td align="center" valign="middle">659/2837 (23)</td><td align="center" valign="middle">299/1104 (27)</td><td align="center" valign="middle">0.01</td></tr><tr><td align="left" valign="bottom">Current or previous smoker</td><td align="center" valign="middle">348/2055 (17)</td><td align="center" valign="middle">409/1066 (38)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Corticosteroid treatment within 2wk prior to COVID-19 diagnosis</td><td align="center" valign="middle">40/1041 (4)</td><td align="center" valign="middle">189/1097 (17)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom"><bold>Presenting symptoms</bold></td><td align="center" valign="middle">981/1061 (92)</td><td align="center" valign="middle">813/1102 (74)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Cough</td><td align="center" valign="middle">685/1061 (65)</td><td align="center" valign="middle">505/1102 (46)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Fever</td><td align="center" valign="middle">698/1061 (66)</td><td align="center" valign="middle">498/1102 (45)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Shortness of breath</td><td align="center" valign="middle">508/1061 (48)</td><td align="center" valign="middle">387/1102 (35)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Chest pain</td><td align="center" valign="middle">100/1061 (9)</td><td align="center" valign="middle">66/1102 (6)</td><td align="center" valign="middle">0.003</td></tr><tr><td align="left" valign="bottom">Headache</td><td align="center" valign="middle">133/1061 (13)</td><td align="center" valign="middle">80/1102 (7)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Gastrointestinal symptoms</td><td align="center" valign="middle">148/1061 (14)</td><td align="center" valign="middle">104/1102 (9)</td><td align="center" valign="middle">0.001</td></tr><tr><td align="left" valign="bottom">Loss of smell</td><td align="center" valign="middle">84/1061 (8)</td><td align="center" valign="middle">58/1102 (5)</td><td align="center" valign="middle">0.013</td></tr><tr><td align="left" valign="bottom">Loss of taste</td><td align="center" valign="middle">78/1061 (7)</td><td align="center" valign="middle">55/1102 (5)</td><td align="center" valign="middle">0.022</td></tr><tr><td align="left" valign="bottom"><bold>ICU admission</bold></td><td align="center" valign="middle">225/1846 (12)</td><td align="center" valign="middle">141/1100 (13)</td><td align="center" valign="middle">0.62</td></tr><tr><td align="left" valign="bottom"><bold>Abnormal laboratory values</bold></td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">ANC &lt;0.5K/μl</td><td align="center" valign="middle">2/1434 (0.1)</td><td align="center" valign="middle">30/419 (7)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">ALC &lt;0.5K/μl</td><td align="center" valign="middle">487/1537 (32)</td><td align="center" valign="middle">225/463 (49)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Platelet count&lt;100K/μl</td><td align="center" valign="middle">187/1446 (13)</td><td align="center" valign="middle">151/387 (39)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Hemoglobin&lt;10g/dL</td><td align="center" valign="middle">437/1533 (29)</td><td align="center" valign="middle">283/601 (47)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">D-dimer, median (range), μg/ml</td><td align="center" valign="middle">1.51 (0.04–735.0)</td><td align="center" valign="middle">1.95 (0.25–93.24)</td><td align="center" valign="middle">0.013</td></tr><tr><td align="left" valign="bottom">Ferritin, median (range), ng/ml</td><td align="center" valign="middle">823 (1.10–89672)</td><td align="center" valign="middle">1015 (1.5–100001)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Procalcitonin, median (range), ng/ml</td><td align="center" valign="middle">0.21 (0.009–163.5)</td><td align="center" valign="middle">0.25 (0–101.8)</td><td align="center" valign="middle">0.008</td></tr><tr><td align="left" valign="bottom">IL-6, median (range), pg/ml</td><td align="center" valign="middle">61 (0–5001)</td><td align="center" valign="middle">44 (0–7525)</td><td align="center" valign="middle">0.13</td></tr><tr><td align="left" valign="bottom"><bold>Imaging findings</bold></td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">New infiltrates</td><td align="center" valign="middle">151/622 (24)</td><td align="center" valign="middle">138/424 (33)</td><td align="center" valign="middle">0.003</td></tr><tr><td align="left" valign="bottom">Ground-glass opacities</td><td align="center" valign="middle">487/622 (78)</td><td align="center" valign="middle">287/425 (68)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Peripheral distribution of infiltrates</td><td align="center" valign="middle">253/622 (41)</td><td align="center" valign="middle">60/347 (17)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom"><bold>Treatment</bold></td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Hydroxychloroquine</td><td align="center" valign="middle">475/2054 (23)</td><td align="center" valign="middle">196/1114 (18)</td><td align="center" valign="middle">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Azithromycin</td><td align="center" valign="middle">972/2054 (47)</td><td align="center" valign="middle">201/1114 (18)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Remdesivir</td><td align="center" valign="middle">338 (12)</td><td align="center" valign="middle">97 (9)</td><td align="center" valign="middle">0.004</td></tr><tr><td align="left" valign="bottom">Tocilizumab</td><td align="center" valign="middle">75/2054 (4)</td><td align="center" valign="middle">67 (6)</td><td align="center" valign="middle">0.002</td></tr><tr><td align="left" valign="bottom">Convalescent plasma</td><td align="center" valign="middle">253/2054 (12)</td><td align="center" valign="middle">61/948 (6)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Steroids</td><td align="center" valign="middle">879/2054 (43)</td><td align="center" valign="middle">192/1114 (17)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Others*</td><td align="center" valign="middle">166/2054 (8)</td><td align="center" valign="middle">124/953 (13)</td><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom"><bold>Outcomes</bold></td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Co-infection after COVID-19 diagnosis</td><td align="center" valign="middle">158/1994 (8)</td><td align="center" valign="middle">116/1066 (11)</td><td align="center" valign="middle">0.006</td></tr><tr><td align="left" valign="bottom">Multi-organ failure</td><td align="center" valign="middle">130/1052 (12)</td><td align="center" valign="middle">135/1096 (12)</td><td align="center" valign="middle">0.98</td></tr><tr><td align="left" valign="bottom">Thrombotic complication</td><td align="center" valign="middle">56/1048 (5)</td><td align="center" valign="middle">48/1072 (5)</td><td align="center" valign="middle">0.36</td></tr><tr><td align="left" valign="bottom">Discharged on supplemental oxygen among hospitalized</td><td align="center" valign="middle">90/776 (12)</td><td align="center" valign="middle">75/438 (17)</td><td align="center" valign="middle">0.007</td></tr><tr><td align="left" valign="bottom">patients</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Hospital re-admission within 30 days of COVID-19 diagnosis</td><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">No</td><td align="center" valign="middle">667/806 (83)</td><td align="center" valign="middle">318/481 (66)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Yes</td><td align="center" valign="middle">60/806 (7)</td><td align="center" valign="middle">63/481 (13)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Stayed in hospital (throughout 30 days)</td><td align="center" valign="middle">79/806 (10)</td><td align="center" valign="middle">100/481 (21)</td><td align="center" valign="middle"/></tr><tr><td align="left" valign="bottom">Death within 30 days of COVID-19 diagnosis</td><td align="center" valign="middle">226 (8)</td><td align="center" valign="middle">122 (11)</td><td align="center" valign="middle">0.003</td></tr></tbody></table><table-wrap-foot><fn><p>Note:*Other treatment included chloroquine, favipiravir, lopinavir-ritonavir, anakina, baricitinib, type 1 interferons, and immunoglobulin.</p></fn><fn><p>Note: If a variable had missing data then the number of patients evaluable for this variable is added as denominator in its analysis result.</p></fn><fn><p>COPD = Chronic obstructive pulmonary disease; ANC = Absolute neutrophil count; ALC = Absolute lymphocyte count; IL-1=interleukin 1; IL-6=Interleukin 6; NA = Not applicable.</p></fn></table-wrap-foot></table-wrap><p>Compared to patients without cancer, patients with cancer were more likely to present with neutropenia (7 vs 0.1%; p&lt;0.0001), lymphocytopenia (49 vs 32%; p&lt;0.0001), thrombocytopenia (39 vs 13%; p&lt;0.0001), and anemia (47 vs 29%; p&lt;0.0001) and had higher median levels of inflammatory biomarkers, including D-dimer (1.95 vs 1.51 μg/ml, p=0.013), ferritin (1015 vs 823 ng/ml, p&lt;0.0001), and procalcitonin (0.25 vs 0.21 ng/ml, p=0.008). On imaging studies (CT), patients with cancer were less likely than patients without cancer to be present with ground-glass opacities (68 vs 78%; p&lt;0.0001) or peripheral distribution of the infiltrates (17 vs 41%; p&lt;0.0001).</p></sec><sec id="s3-2"><title>Treatment and outcomes of patients with and without cancer</title><p>For most treatments for COVID-19 infection, patients without cancer were more likely to receive them than patients with cancer, including hydroxychloroquine (23 vs 18%, p&lt;0.001), azithromycin (47 vs 18%, p&lt;0.0001), remdesivir (12 vs 9%, p=0.004), convalescent plasma (12 vs 6%, &lt;0.0001), and steroids (43 vs 17%, p&lt;0.0001). However, patients with cancer were more likely to receive tocilizumab (6 vs 4%, p=0.002). In addition, the treatments patients received for COVID-19 infection significantly differed among the countries (data not shown). The rate of COVID-related hospital admission was higher in the patients without cancer (62 vs 45%; p&lt;0.0001). Co-infections occurred more frequently in patients with cancer (11 vs 8%; p=0.006). Among hospitalized patients, patients with cancer were more likely than patients without cancer to be discharged on supplemental oxygen (17 vs 12%; p=0.007). Likewise, the rate of hospital readmission within 30 days was higher in patients with cancer (13 vs 7%; p&lt;0.0001). Furthermore, the mortality rate within 30 days was also significantly higher in patients with cancer by univariable analyses (11 vs 8%; p=0.003; <xref ref-type="table" rid="table1">Table 1</xref>).</p></sec><sec id="s3-3"><title>Risk factors for death within 30 days after COVID-19 diagnosis</title><p>The independent predictors of 30 day mortality among all patients identified by the multivariable analysis are shown in <xref ref-type="table" rid="table2">Table 2</xref>. The multivariable complete-case analysis also showed that cancer was not an independent risk factor for 30 day mortality (p=0.18; <xref ref-type="table" rid="table2">Table 2</xref>). Older age (≥65y) was the strongest predictor of 30 day mortality in all patients (OR = 4.47; 95%CI=3.27–6.11; p&lt;0.0001; <xref ref-type="table" rid="table2">Table 2</xref>) and in both patients with (OR = 6.64, p&lt;0.0001) and without cancer (OR = 4.91, p&lt;0.0001; <xref ref-type="table" rid="table3">Table 3</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Country-adjusted multivariars of 30 day mortality among all patients.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="2">Independent predictor</th><th align="center" valign="bottom" colspan="3">Complete Case (CC)</th><th align="center" valign="bottom" colspan="3">Multiple imputation (MI)</th></tr><tr><th align="center" valign="bottom" colspan="3">(N=2349)</th><th align="center" valign="bottom" colspan="3">(N=3966)</th></tr><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">aOR</th><th align="left" valign="bottom">95%CI</th><th align="left" valign="bottom">p-value</th><th align="left" valign="bottom">aOR</th><th align="left" valign="bottom">95%CI</th><th align="left" valign="bottom">p-value</th></tr></thead><tbody><tr><td align="left" valign="bottom">Age ≥65y</td><td align="center" valign="bottom">4.47</td><td align="center" valign="bottom">(3.27, 6.11)</td><td align="center" valign="bottom">&lt;0.0001</td><td align="center" valign="bottom">4.73</td><td align="center" valign="bottom">(3.54, 6.32)</td><td align="center" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Prior COPD/bronchiolitis obliterans</td><td align="center" valign="bottom">1.95</td><td align="center" valign="bottom">(1.33, 2.85)</td><td align="center" valign="bottom">&lt;0.001</td><td align="center" valign="bottom">1.73</td><td align="center" valign="bottom">(1.21, 2.48)</td><td align="center" valign="bottom">0.003</td></tr><tr><td align="left" valign="bottom">History of heart failure</td><td align="center" valign="bottom">1.61</td><td align="center" valign="bottom">(1.13, 2.28)</td><td align="center" valign="bottom">0.008</td><td align="center" valign="bottom">1.64</td><td align="center" valign="bottom">(1.17, 2.29)</td><td align="center" valign="bottom">0.004</td></tr><tr><td align="left" valign="bottom">History of hypertension</td><td align="center" valign="bottom">1.44</td><td align="center" valign="bottom">(1.03, 2.01)</td><td align="center" valign="bottom">0.036</td><td align="center" valign="bottom">1.52</td><td align="center" valign="bottom">(1.11, 2.07)</td><td align="center" valign="bottom">0.008</td></tr><tr><td align="left" valign="bottom">Cancer</td><td align="center" valign="bottom">1.30</td><td align="center" valign="bottom">(0.89, 1.90)</td><td align="center" valign="bottom">0.18</td><td align="center" valign="bottom">1.23</td><td align="center" valign="bottom">(0.87, 1.75)</td><td align="center" valign="bottom">0.24</td></tr><tr><td align="left" valign="bottom">Hypoxia at diagnosis</td><td align="center" valign="bottom">4.58</td><td align="center" valign="bottom">(2.92, 7.19)</td><td align="center" valign="bottom">&lt;0.0001</td><td align="center" valign="bottom">5.74</td><td align="center" valign="bottom">(3.91, 8.45)</td><td align="center" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Mechanical ventilation/intubation at diagnosis</td><td align="center" valign="bottom">2.20</td><td align="center" valign="bottom">(1.23, 3.93)</td><td align="center" valign="bottom">0.008</td><td align="center" valign="bottom">2.23</td><td align="center" valign="bottom">(1.30, 3.84)</td><td align="center" valign="bottom">0.004</td></tr><tr><td align="left" valign="bottom">ALC at diagnosis &lt;0.5K/µl</td><td align="center" valign="bottom">1.86</td><td align="center" valign="bottom">(1.30, 2.64)</td><td align="center" valign="bottom">&lt;0.001</td><td align="center" valign="bottom">1.79</td><td align="center" valign="bottom">(1.27, 2.51)</td><td align="center" valign="bottom">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Creatinine at diagnosis &gt;1.5mg/dl</td><td align="center" valign="bottom">1.68</td><td align="center" valign="bottom">(1.21, 2.31)</td><td align="center" valign="bottom">0.002</td><td align="center" valign="bottom">1.70</td><td align="center" valign="bottom">(1.22, 2.38)</td><td align="center" valign="bottom">0.002</td></tr><tr><td align="left" valign="bottom">Hemoglobin at diagnosis &lt;10g/dl</td><td align="center" valign="bottom">1.54</td><td align="center" valign="bottom">(1.06, 2.25)</td><td align="center" valign="bottom">0.024</td><td align="center" valign="bottom">1.67</td><td align="center" valign="bottom">(1.18, 2.38)</td><td align="center" valign="bottom">0.004</td></tr><tr><td align="left" valign="bottom">Coinfection after diagnosis</td><td align="center" valign="bottom">1.83</td><td align="center" valign="bottom">(1.25, 2.68)</td><td align="center" valign="bottom">0.002</td><td align="center" valign="bottom">1.79</td><td align="center" valign="bottom">(1.25, 2.56)</td><td align="center" valign="bottom">0.001</td></tr><tr><td style="author-callout-style-b8">Remdesivir treatment</td><td style="author-callout-style-b8">0.64</td><td style="author-callout-style-b8">(0.42, 0.97)</td><td style="author-callout-style-b8">0.036</td><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/></tr></tbody></table><table-wrap-foot><fn><p>The model was adjusted for country, tocilizumb treatment, and convalescent plasma treatment.</p></fn><fn><p>The significant difference between the models by CC analysis and by MI analysis was shown in the gray area - remdesivir treatment was an independent predictor of 30 day mortality in the multivariable model by CC analysis but not in the model by MI analysis.</p></fn><fn><p>COPD=Chronic obstructive pulmonary disease; ALC=Absolute lymphocyte count.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Country-adjusted multivariable logistic regression analysis of independent predictors of 30 day mortality among different patients.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="7">A) Patients with cancer</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="3">Independent predictor</td><td align="center" valign="bottom" colspan="3"><bold>Complete case (CC)</bold></td><td align="center" valign="bottom" colspan="3"><bold>Multiple imputation (MI)</bold></td></tr><tr><td align="center" valign="bottom" colspan="3">(N=557)</td><td align="center" valign="bottom" colspan="3">(N=1115)</td></tr><tr><td align="center" valign="bottom">aOR</td><td align="center" valign="bottom">95%CI</td><td align="center" valign="bottom">p-value</td><td align="center" valign="bottom">aOR</td><td align="center" valign="bottom">95%CI</td><td align="center" valign="bottom">p-value</td></tr><tr><td align="left" valign="bottom">Age ≥65y</td><td align="center" valign="bottom">6.64</td><td align="center" valign="bottom">(3.51, 12.55)</td><td align="center" valign="bottom">&lt;0.0001</td><td align="center" valign="bottom">4.22</td><td align="center" valign="bottom">(2.51, 7.07)</td><td align="center" valign="bottom">&lt;0.0001</td></tr><tr><td style="author-callout-style-b8">History of heart failure</td><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/><td style="author-callout-style-b8">2.29</td><td style="author-callout-style-b8">(1.19, 4.42)</td><td style="author-callout-style-b8">0.014</td></tr><tr><td align="left" valign="bottom">Hypoxia at diagnosis</td><td align="center" valign="bottom">2.52</td><td align="center" valign="bottom">(1.18, 5.35)</td><td align="center" valign="bottom">0.017</td><td align="center" valign="bottom">2.46</td><td align="center" valign="bottom">(1.17, 5.17)</td><td align="center" valign="bottom">0.017</td></tr><tr><td align="left" valign="bottom">Non-invasive ventilation at diagnosis</td><td align="center" valign="bottom">2.13</td><td align="center" valign="bottom">(1.01, 4.53)</td><td align="center" valign="bottom">0.049</td><td align="center" valign="bottom">2.67</td><td align="center" valign="bottom">(1.28, 5.57)</td><td align="center" valign="bottom">0.009</td></tr><tr><td align="left" valign="bottom">ALC at diagnosis &lt;0.5K/µl</td><td align="center" valign="bottom">2.10</td><td align="center" valign="bottom">(1.16, 3.79)</td><td align="center" valign="bottom">0.014</td><td align="center" valign="bottom">1.98</td><td align="center" valign="bottom">(1.14, 3.45)</td><td align="center" valign="bottom">0.017</td></tr><tr><td style="author-callout-style-b8">Hemoglobin at diagnosis &lt;10g/dl</td><td style="author-callout-style-b8">2.40</td><td style="author-callout-style-b8">(1.30, 4.44)</td><td style="author-callout-style-b8">0.005</td><td style="author-callout-style-b8">1.74</td><td style="author-callout-style-b8">(0.98, 3.08)</td><td style="author-callout-style-b8">0.056</td></tr><tr><td style="author-callout-style-b8">Platelet at diagnosis &lt;100K/µl</td><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/><td style="author-callout-style-b8">2.21</td><td style="author-callout-style-b8">(1.15, 4.24)</td><td style="author-callout-style-b8">0.017</td></tr><tr><td align="left" valign="bottom">LRTI at diagnosis or progression to LRTI</td><td align="center" valign="bottom">3.70</td><td align="center" valign="bottom">(1.94, 7.08)</td><td align="center" valign="bottom">&lt;.0001</td><td align="center" valign="bottom">4.16</td><td align="center" valign="bottom">(1.95, 8.82)</td><td align="center" valign="bottom">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Remdesivir treatment</td><td align="center" valign="bottom">0.44</td><td align="center" valign="bottom">(0.20, 0.96)</td><td align="center" valign="bottom">0.04</td><td align="center" valign="bottom">0.45</td><td align="center" valign="bottom">(0.21, 0.98)</td><td align="center" valign="bottom">0.04</td></tr><tr><th align="left" valign="bottom" colspan="7">B) Patients without cancer</th></tr><tr><td align="left" valign="bottom" rowspan="3">Independent predictor</td><td align="center" valign="middle" colspan="3"><bold>Complete Case (CC</bold>)</td><td align="center" valign="middle" colspan="3"><bold>Multiple Imputation (MI</bold>)</td></tr><tr><td align="center" valign="bottom" colspan="3">(N=1777)</td><td align="center" valign="bottom" colspan="3">(N=2851)</td></tr><tr><td align="center" valign="bottom">aOR</td><td align="center" valign="bottom">95%CI</td><td align="center" valign="bottom">p-value</td><td align="center" valign="bottom">aOR</td><td align="center" valign="bottom">95%CI</td><td align="center" valign="bottom">p-value</td></tr><tr><td align="left" valign="bottom">Age ≥65y</td><td align="center" valign="bottom">4.91</td><td align="center" valign="bottom">(3.39, 7.13)</td><td align="center" valign="bottom">&lt;.0001</td><td align="center" valign="bottom">4.96</td><td align="center" valign="bottom">(3.46, 7.10)</td><td align="center" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Prior COPD/bronchiolitis obliterans</td><td align="center" valign="bottom">1.81</td><td align="center" valign="bottom">(1.16, 2.83)</td><td align="center" valign="bottom">0.009</td><td align="center" valign="bottom">1.84</td><td align="center" valign="bottom">(1.19, 2.84)</td><td align="center" valign="bottom">0.006</td></tr><tr><td align="left" valign="bottom">History of ishemic heart disease</td><td align="center" valign="bottom">1.68</td><td align="center" valign="bottom">(1.10, 2.56)</td><td align="center" valign="bottom">0.017</td><td align="center" valign="bottom">1.69</td><td align="center" valign="bottom">(1.12, 2.56)</td><td align="center" valign="bottom">0.013</td></tr><tr><td align="left" valign="bottom">History of hypertension</td><td align="center" valign="bottom">1.98</td><td align="center" valign="bottom">(1.30, 3.03)</td><td align="center" valign="bottom">0.002</td><td align="center" valign="bottom">2.15</td><td align="center" valign="bottom">(1.42, 3.24)</td><td align="center" valign="bottom">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Hypoxia at diagnosis</td><td align="center" valign="bottom">7.53</td><td align="center" valign="bottom">(3.72, 15.26)</td><td align="center" valign="bottom">&lt;0.0001</td><td align="center" valign="bottom">7.91</td><td align="center" valign="bottom">(4.22, 14.86)</td><td align="center" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">Mechanical ventilation/intubation</td><td align="center" valign="bottom">2.38</td><td align="center" valign="bottom">(1.22, 4.62)</td><td align="center" valign="bottom">0.011</td><td align="center" valign="bottom">2.15</td><td align="center" valign="bottom">(1.13, 4.08)</td><td align="center" valign="bottom">0.019</td></tr><tr><td align="left" valign="bottom">At diagnosis</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td style="author-callout-style-b8">ALC at diagnosis &lt;0.5K/µl</td><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/><td style="author-callout-style-b8"/><td style="author-callout-style-b8">1.62</td><td style="author-callout-style-b8">(1.01, 2.59)</td><td style="author-callout-style-b8">0.044</td></tr><tr><td align="left" valign="bottom">Creatinine at diagnosis &gt;1.5mg/dL</td><td align="center" valign="bottom">1.96</td><td align="center" valign="bottom">(1.35, 2.84)</td><td align="center" valign="bottom">&lt;0.001</td><td align="center" valign="bottom">1.95</td><td align="center" valign="bottom">(1.32, 2.87)</td><td align="center" valign="bottom">&lt;0.001</td></tr><tr><td align="left" valign="bottom">Coinfection after diagnosis</td><td align="center" valign="bottom">3.03</td><td align="center" valign="bottom">(1.87, 4.89)</td><td align="center" valign="bottom">&lt;0.0001</td><td align="center" valign="bottom">2.83</td><td align="center" valign="bottom">(1.79, 4.48)</td><td align="center" valign="bottom">&lt;0.0001</td></tr></tbody></table><table-wrap-foot><fn><p>ALC=Absolute lymphocyte count; LRTI=Lower respiratory tract infection; COPD=Chronic obstructive pulmonary disease.</p></fn><fn><p>The model was adjusted for country and tocilizumb treatment.</p></fn><fn><p>The significant differences between the models by CC analysis and by MI analysis were shown in the gray area - (a) History of heart failure and platelet level at diagnosis were independent predictors of 30 day mortality in the multivariable model by MI analysis, but not in the model by CC analysis; (b) Hemoglobin level at diagnosis was an independent predictor of 30 day mortality in the multivariable model by CC analysis, but not in the model by MI analysis.</p></fn><fn><p>Hemoglobin level at diagnosis was kept in the final model by MI analysis due to its confounding effect despite its non-significant p-value.</p></fn><fn><p>The model was adjusted for country and convalescent plasma treatment.</p></fn><fn><p>The significant difference between the models by CC analysis and by MI analysis was shown in the gray area - ALC level at diagnosis was an independent predictor of 30 day mortality in the multivariable model by MI analysis, but not in the model by CC analysis.</p></fn></table-wrap-foot></table-wrap><p>Other independent risk factors for 30 day mortality in all patients included hypoxia at diagnosis (OR = 4.58; p&lt;0.0001), need for mechanical ventilation (OR = 2.20; p=0.008), and presence of co-infection (OR = 1.83; p=0.002; <xref ref-type="table" rid="table2">Table 2</xref>).</p><p>In patients with cancer, lower respiratory tract infection manifested by the presence of pulmonary infiltrates either at diagnosis or during the course of infection was a strong independent predictor of 30 day mortality (OR = 3.70; 95% CI = 1.94–7.08; p&lt;0.0001; <xref ref-type="table" rid="table3">Table 3</xref>).</p><p>Among patients with cancer, the 30 day mortality rate was significantly higher in patients with lung cancer (22%) than in patients with non-lung cancer solid tumors (6%, p&lt;0.0001), including those with lung metastases (7%, p&lt;0.001; <xref ref-type="table" rid="table4">Table 4</xref>). Patients with hematological malignancies had a significantly higher 30 day mortality than patients with non-lung cancer solid tumors (13 vs 6%, p&lt;0.001) but tended to have a lower mortality rate than patients with lung cancer (13 vs 22%, p=0.07; <xref ref-type="table" rid="table4">Table 4</xref>). However, we did not find a significant difference in mortality between hematological malignancies and solid tumors by multivariable analysis (p=0.30).</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>30 day mortality among different groups of COVID-19 patients with cancer.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Patient group</th><th align="left" valign="bottom" colspan="2">No. of patients</th><th align="left" valign="bottom" colspan="2">No. (%) who died within 30 days<xref ref-type="table-fn" rid="table4fn2"><sup>†</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Hematological malignancy</bold></td><td align="left" valign="bottom" colspan="2"><bold>283</bold></td><td align="left" valign="bottom" colspan="2"><bold>37</bold> (<bold>13</bold>)</td></tr><tr><td align="left" valign="bottom">Transplant within 1y of COVID-19 diagnosis</td><td align="left" valign="bottom" colspan="2">15</td><td align="left" valign="bottom" colspan="2">2 (13)</td></tr><tr><td align="left" valign="bottom">Lymphoma or myeloma</td><td align="left" valign="bottom" colspan="2">164</td><td align="left" valign="bottom" colspan="2">19 (12)</td></tr><tr><td align="left" valign="bottom">Lymphocytic leukemia (ALL/CLL)</td><td align="left" valign="bottom" colspan="2">44</td><td align="left" valign="bottom" colspan="2">6 (14)</td></tr><tr><td align="left" valign="bottom">Myelocytic leukemia</td><td align="left" valign="bottom" colspan="2">62</td><td align="left" valign="bottom" colspan="2">8 (13)</td></tr><tr><td align="left" valign="bottom"><bold>Solid tumor</bold><xref ref-type="table-fn" rid="table4fn1">*</xref></td><td align="left" valign="bottom" colspan="2"><bold>632</bold></td><td align="left" valign="bottom" colspan="2"><bold>47</bold> (<bold>7</bold>)</td></tr><tr><td align="left" valign="bottom">Lung cancer</td><td align="left" valign="bottom" colspan="2">64</td><td align="left" valign="bottom" colspan="2">14 (22)</td></tr><tr><td align="left" valign="bottom">Metastatic non-lung cancer solid tumor</td><td align="left" valign="bottom" colspan="2">261</td><td align="left" valign="bottom" colspan="2">17 (7)</td></tr><tr><td align="left" valign="bottom">Non-metastatic non-lung cancer solid tumor</td><td align="left" valign="bottom" colspan="2">307</td><td align="left" valign="bottom" colspan="2">16 (5)</td></tr></tbody></table><table-wrap-foot><fn id="table4fn1"><label>*</label><p>Patients with missing metastasis data were excluded from the analysis.</p></fn><fn id="table4fn2"><label>†</label><p>30 day mortality comparisons for the groups below. (1) Lung cancer vs metastatic non-lung cancer solid tumor: p&lt; 0.001; (2) Lung cancer vs non-metastatic non-lung cancer solid tumor: p&lt; 0.0001; (3) Hematological malignancy vs lung cancer: p=0.07; (4) Hematological malignancy vs non-lung cancer solid tumor: p&lt; 0.001; (5) None of the above significant differences detected remained significant in multivariable analysis of 30 d mortality in cancer patients.</p></fn></table-wrap-foot></table-wrap><p>By multivariable analysis, remdesivir was the only therapeutic agent independently associated with decreased 30 day all-cause mortality in all patients (OR = 0.64; 95% CI = 0.42–0.97; p=0.036; <xref ref-type="table" rid="table2">Table 2</xref>), and in patients with cancer (OR = 0.44; 95% CI = 0.20–0.96; p=0.04) as well (<xref ref-type="table" rid="table3">Table 3</xref>). However, in patients without cancer, remdesivir was not among the factors independently associated with mortality by multivariable analysis (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>Among patients on low-flow oxygen at admission, the mortality rate was lower among those who received remdesivir than among those who did not (5.9 [3 of 51] vs 17.6% [68 of 387]; p=0.03). However, among patients on high-flow oxygen at admission, there was no difference in the mortality rate between patients who received remdesivir and those who did not (29.7 [11 of 37] and 34.4% [53 of 154], respectively; p=0.59).</p><p>Since 85% of patients treated with remdesivir also received corticosteroids, we evaluated the impact of their combination therapy on 30 day mortality. Among patients on low-flow oxygen at admission, the mortality rates among those who received remdesivir alone or in combination with corticosteroids (6% [3 of 51]) was significantly lower than the mortality rate of those who received corticosteroids alone (18.3% [21 of 115]; p=0.036). However, mortality rates were similar for remdesivir alone and combination therapy among various patients’ groups (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p><p>Giving convalescent plasma to patients later than 3d after diagnosis did not make any difference in mortality (data not shown). In contrast to what was observed for convalescent plasma, the later corticosteroids were administered, the greater the benefit. There was a trend toward a greater reduction in 30 day mortality in patients who received corticosteroids later (&gt;5d after diagnosis), whereas no difference was observed in patients who received corticosteroids earlier (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p></sec><sec id="s3-4"><title>Sensitivity analysis</title><p>Lastly, sensitivity analyses were performed to evaluate the impact of missing data on our primary analyses. The multivariable logistic regression models of mortality predictors based on the complete-case analysis and multiple imputation analysis were compared for all patients (<xref ref-type="table" rid="table2">Table 2</xref>) and for patients with and without cancer (<xref ref-type="table" rid="table3">Table 3</xref>). Among all patients, the two models were similar except that multiple imputation analyses did not show remdesivir having a significant impact on mortality while the complete-case analysis did (<xref ref-type="table" rid="table2">Table 2</xref>). However, among patients with cancer, both models showed that remdesivir was independently associated with decreased mortality with similar effects. On the other hand, the two models showed some differences in identifying a few risk factors for 30 day mortality. Among patients without cancer, the two models were similar except that multiple imputation analysis identified one more risk factor – ALC&lt;0.5K/µl at diagnosis (<xref ref-type="table" rid="table3">Table 3</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Unlike the previously published studies that compared patients with COVID-19 with and without cancer, our study included a large number of patients with cancer from five different continents. Our findings demonstrate that cancer is not an independent risk factor for increased 30 day all-cause mortality in a multivariable logistic regression analyses that accounted for the treatment differences among the countries, which is inconsistent with a recent large study in the US that showed that patients recently receiving cancer treatment had a worse outcome (<xref ref-type="bibr" rid="bib3">Chavez-MacGregor et al., 2022</xref>). The higher mortality rate observed in patients with cancer by univariable analysis seems to be driven by patients with lung cancer and patients with hematological malignancies, a finding that is consistent with prior literature (<xref ref-type="bibr" rid="bib12">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Mehta et al., 2020</xref>). Furthermore, lymphopenia which is observed frequently in patients with hematological malignancy was independently associated with higher COVID-19 mortality according to our country-adjusted multivariable analyses. Two large studies in COVID-19 patients with cancer have shown that lymphopenia was independently associated with increased 30 day mortality (<xref ref-type="bibr" rid="bib14">Lunski et al., 2021</xref>; <xref ref-type="bibr" rid="bib24">Schmidt et al., 2022</xref>). In addition, the mortality rate in the patients with solid tumors other than lung cancer was not different from the mortality rate in the patients without cancer.</p><p>Most of the other independent risk factors that we identified for 30 day mortality after a diagnosis of COVID-19 have also been commonly reported as risk factors for mortality in previous studies of COVID-19 in patients with and without cancer with older age (≥65y) being the strongest independent predictor of 30 day mortality in our study (<xref ref-type="bibr" rid="bib31">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Kuderer et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Rivera et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Albiges et al., 2020</xref>; <xref ref-type="bibr" rid="bib21">Robilotti et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Lee et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Mehta et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Tian et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Lunski et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Sun et al., 2020</xref>; <xref ref-type="bibr" rid="bib22">Rüthrich et al., 2021</xref>). In our study, the patients with cancer had a more complicated course after discharge from the hospital; specifically, they more frequently required supplemental oxygen and readmission within 30 days after COVID-19 diagnosis.</p><p>The presentation pattern of COVID-19 in patients with cancer was different to that of patients without cancer. Patients with cancer seemed to be less symptomatic. This could be related to the fact that patients with cancer tended to be older, with fewer inflammatory cells (neutrophils and lymphocytes), and more often on corticosteroids. Levels of inflammatory biomarkers were also higher in patients with cancer, particularly D-dimer, ferritin, and procalcitonin.</p><p>On multivariable analysis, the only therapeutic agent that independently decreased 30 day all-cause mortality among all patients and in patients with cancer was remdesivir, even after accounting for treatment diffrences among countries. Upon further analysis, remdesivir was found to further decrease mortality in patients with pneumonia and mild hypoxia who were receiving low-flow oxygen (≤6l/min) and not in patients with severe advanced pneumonia who were receiving high-flow oxygen and/or ventilatory support. This is consistent with a large multicenter prospective randomized placebo-controlled trial - Adaptive COVID-19 Treatment Trial-1 (ACTT-1), that found that remdesivir significantly reduced the time to recovery and 28d mortality in patients who were on low-flow oxygen at baseline but not in patients who were on mechanical ventilation or extracorporeal membrane oxygenation at baseline (<xref ref-type="bibr" rid="bib2">Beigel et al., 2020</xref>).</p><p>In a meta-analysis that examined four large prospective randomized trials, remdesivir was shown to be associated with reduced 14 d mortality and reduced need for mechanical ventilation (<xref ref-type="bibr" rid="bib25">Shrestha et al., 2021</xref>), which also supports our analysis.</p><p>In contrast, the WHO-sponsored multinational Solidarity Trial of COVID-19 hospitalized patients who were randomly assigned to either remdesivir (2750patients) or standard of care (2708patients) showed no difference in overall 28d mortality (<xref ref-type="bibr" rid="bib17">Pan et al., 2021</xref>). However, in two large meta-analyses that each examined more than 13,000 COVID-19 patients from randomized and non-randomized studies, including the WHO randomized trial, remdesivir was associated with a significant improvement in the 28d recovery rate (<xref ref-type="bibr" rid="bib19">Rezagholizadeh et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Lai et al., 2021</xref>). Furthermore, in a large study evaluating treatments and outcomes of COVID-19 among patients with cancer, remdesivir alone was significantly associated with a lower 30 day all-cause mortality rate than other treatments (including high-dose corticosteroids and tocilizumab; <xref ref-type="bibr" rid="bib20">Rivera et al., 2020</xref>). In addition, in a large multicenter matched controlled study involving mostly patients without cancer, Mozaffari et al. demonstrated that remdesivir was significantly effective in reducing mortality in patients on low-flow oxygen but not patients with advanced disease on high-flow oxygen and ventilator support (<xref ref-type="bibr" rid="bib16">Mozaffari et al., 2022</xref>). More recently, a prospective randomized, double blind, placebo-controlled study (involving mainly patients without cancer) showed that early initiation of remdesivir prevents progression to severe COVID-19 (<xref ref-type="bibr" rid="bib4">Gottlieb et al., 2022</xref>).</p><p>Therefore, the cumulative data in the literature do support our findings that remdesivir in all patients particularly in patients with cancer improves outcome and may reduce mortality especially if started early in COVID-19 patients with moderate pneumonia who are receiving low-flow oxygen who fit into the stage II of the three-stage COVID-19 classification previously proposed by <xref ref-type="bibr" rid="bib26">Siddiqi and Mehra, 2020</xref>.</p><p>The use of corticosteroids (dexamethasone 6mg/d) was shown in a large randomized open-label study conducted in the United Kingdom to be associated with reduced 28d mortality, particularly in patients requiring oxygen supplementation and invasive ventilation who receive corticosteroids after 7d from the onset of symptoms (<xref ref-type="bibr" rid="bib6">Horby et al., 2021</xref>). Subsequently, two meta-analyses of several prospective randomized trials demonstrated that corticosteroid use was significantly associated with a decrease in COVID-19 mortality (<xref ref-type="bibr" rid="bib28">Sterne et al., 2020</xref>; <xref ref-type="bibr" rid="bib27">Siemieniuk et al., 2020</xref>). In our study, we found that if corticosteroids were started more than 5d after the PCR diagnosis of COVID-19, there was a trend toward a reduction in 30 day COVID-19 mortality compared to starting corticosteroids earlier. 5 d after diagnosis by PCR testing would possibly be equivalent to 7d after the onset of symptoms since the average time from symptom onset to PCR diagnosis has been estimated to be 2–3d (<xref ref-type="bibr" rid="bib9">Kucirka et al., 2020</xref>). Furthermore, by multivariable analysis and upon further subanalysis (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>), remdesivir was found to improve outcome independently of the effect of steroids.</p><p>Our study has several limitations. First, the retrospective design precluded complete assessment of disease progression in the outpatients, which limited their input into the general study. Second, some non-cancer centers contributed data only on their hospitalized patients who were likely sicker. This may have biased the data toward a higher rate of hospitalization among patients without cancer and made the data more heterogeneous. In addition, the predominance of symptomatic patients (87%) might also limit our evaluation of the impact of cancer in the whole picture of the disease. Third, our data contained a lot of missing values due to the nature of data collection. However, we performed sensitivity analyses to evaluate its impact on our primary analyses, and it showed that overall this impact was limited. Most independent predictors were identified by both complete-case and multiple imputation analyses with similar effects. The differences between the two analysis methods in identifying a few independent mortality predictors were probably due to the sample size changes from complete-case analyses to multiple imputation analyses. Last, this study was conducted prior to the introduction of COVID vaccines and included patients who were not vaccinated and who were infected by early variants which limits the generalizability of our results to contemporary COVID-19 patients. A multinational European registry showed that severity of COVID-19 and mortality in cancer patients have improved since 2020. This could be multifactorial related to earlier diagnosis, improved management including current antivirals, monoclonal antibodies, vaccination, as well as different circulating variants of the virus that could be associated with less severe disease than the earlier strains (<xref ref-type="bibr" rid="bib18">Pinato et al., 2022</xref>). However, a recent study comparing vaccinated and unvaccinated patients with cancer showed that despite the protective role of vaccination, vulnerable patients with cancer, particularly those with risk factors such as lymphopenia, active and progressing cancer, and advanced age, can develop severe and fatal breakthrough infections (<xref ref-type="bibr" rid="bib24">Schmidt et al., 2022</xref>).</p><p>In conclusion, this is the largest multicenter worldwide study comparing COVID-19 in patients with cancer to those without. In this study, although the limited effect size, underlying malignancy was not found to be an independent risk factor for a higher 30 day all-cause COVID-19 mortality. However, lymphopenia and anemia were frequently observed in patients with hematological malignancies, and patients with lung cancer were associated with the highest risks for poor outcome. Finally, remdesivir stood out as the only therapeutic agent independently associated with decreased 30 day mortality, particularly in patients with cancer on low-flow oxygen. Corticosteroids tended to be most useful if given more than 5d after COVID-19 diagnosis. The role of these therapeutics and their timing of administration should be verified in larger studies, especially in patients with cancer, who tend to have a higher degree of immunosuppression, which may lead to prolongation of the viral phase.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Supervision, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Data curation, Supervision, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Resources, Data curation, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con22"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con23"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con24"><p>Conceptualization, Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con25"><p>Conceptualization, Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con26"><p>Conceptualization, Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con27"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con28"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con29"><p>Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con30"><p>Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con31"><p>Conceptualization, Resources, Data curation, Validation, Investigation</p></fn><fn fn-type="con" id="con32"><p>Conceptualization, Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con33"><p>Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con34"><p>Resources, Data curation, Investigation, Visualization</p></fn><fn fn-type="con" id="con35"><p>Data curation, Investigation, Visualization</p></fn><fn fn-type="con" id="con36"><p>Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con37"><p>Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con38"><p>Resources, Data curation, Supervision, Investigation, Visualization</p></fn><fn fn-type="con" id="con39"><p>Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con40"><p>Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con41"><p>Resources, Data curation, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con42"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con43"><p>Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con44"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization</p></fn><fn fn-type="con" id="con45"><p>Conceptualization, Resources, Data curation, Software, Supervision, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con46"><p>Conceptualization, Resources, Data curation, Supervision, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con47"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con48"><p>Conceptualization</p></fn><fn fn-type="con" id="con49"><p>Resources, Data curation, Investigation</p></fn><fn fn-type="con" id="con50"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con51"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: This study (Protocol # 2020-0437) was approved by the institutional review board at MD Anderson Cancer Center and the institutional review boards of the collaborating centers. A patient waiver of informed consent was obtained.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Comparing mortality in patients treated with remdesivir alone or with steroids for COVID-19.</title></caption><media xlink:href="elife-81127-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Timing of administration of corticosteroids as COVID-19 treatment and 30 d mortality.</title></caption><media xlink:href="elife-81127-supp2-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81127-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>We are unable to share the data given our restriction policy and the fact that this study includes data from 16 centers and from the five continents. We do not have an agreement or the permission to share our data and other centers’ data. All the analyses were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank all the investigators, MD Anderson Cancer Network, and the Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team at The University of Texas MD Anderson Cancer Center for assistance in study development and data extraction. We thank Ms. Meena Medepalli and Mr. Joel Cox from the MD Anderson Cancer Network - External Research at The University of Texas MD Anderson Cancer Center for their support in coordinating the cancer network sites for protocol participation. We thank Mr. Joseph P Thomas at The University of Texas MD Anderson Cancer Center for his assistance with data capture in REDCap, Kris Weaver for data quality review, Sheri Rivera for REDCap build, Regulatory team for the fast activation, Toby and her team for assistance in resolving IT issues with site EMR. We thank Anastasia Turin and Drew Goldstein from Syntropy Technologies LLC, Burlington, MA for interfacing with the Syntropy platform: Palantir Foundry. 'Foundry' is Syntropy’s fully-managed, cloud-based software-as-a-service for governing, structuring, and harmonizing real-world data to empower health systems and their collaborators to derive insights from that data. Editorial assistance was provided by Stephanie P Deming, Research Medical Library at MD Anderson. This assistance was funded by The University of Texas MD Anderson Cancer Center. We thank Ms. Salli Saxton and Ms Christine Cobb at The University of Texas MD Anderson Cancer Center for helping with the submission of the manuscript. This research is supported by the National Institutes of Health/National Cancer Institute under award number P30CA016672, which supports the MD Anderson Cancer Center Clinical Trials Office. National Cancer Institute, National Institutes of Health The funders had no role the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albiges</surname><given-names>L</given-names></name><name><surname>Foulon</surname><given-names>S</given-names></name><name><surname>Bayle</surname><given-names>A</given-names></name><name><surname>Gachot</surname><given-names>B</given-names></name><name><surname>Pommeret</surname><given-names>F</given-names></name><name><surname>Willekens</surname><given-names>C</given-names></name><name><surname>Stoclin</surname><given-names>A</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Griscelli</surname><given-names>F</given-names></name><name><surname>Lacroix</surname><given-names>L</given-names></name><name><surname>Netzer</surname><given-names>F</given-names></name><name><surname>Hueso</surname><given-names>T</given-names></name><name><surname>Balleyguier</surname><given-names>C</given-names></name><name><surname>Ammari</surname><given-names>S</given-names></name><name><surname>Colomba</surname><given-names>E</given-names></name><name><surname>Baciarello</surname><given-names>G</given-names></name><name><surname>Perret</surname><given-names>A</given-names></name><name><surname>Hollebecque</surname><given-names>A</given-names></name><name><surname>Hadoux</surname><given-names>J</given-names></name><name><surname>Michot</surname><given-names>J-M</given-names></name><name><surname>Chaput</surname><given-names>N</given-names></name><name><surname>Saada</surname><given-names>V</given-names></name><name><surname>Hauchecorne</surname><given-names>M</given-names></name><name><surname>Micol</surname><given-names>J-B</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Valteau-Couanet</surname><given-names>D</given-names></name><name><surname>André</surname><given-names>F</given-names></name><name><surname>Scotte</surname><given-names>F</given-names></name><name><surname>Besse</surname><given-names>B</given-names></name><name><surname>Soria</surname><given-names>J-C</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Determinants of the outcomes of patients with cancer infected with SARS-cov-2: results from the Gustave Roussy cohort</article-title><source>Nature Cancer</source><volume>1</volume><fpage>965</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-00120-5</pub-id><pub-id pub-id-type="pmid">35121871</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Tomashek</surname><given-names>KM</given-names></name><name><surname>Dodd</surname><given-names>LE</given-names></name><name><surname>Mehta</surname><given-names>AK</given-names></name><name><surname>Zingman</surname><given-names>BS</given-names></name><name><surname>Kalil</surname><given-names>AC</given-names></name><name><surname>Hohmann</surname><given-names>E</given-names></name><name><surname>Chu</surname><given-names>HY</given-names></name><name><surname>Luetkemeyer</surname><given-names>A</given-names></name><name><surname>Kline</surname><given-names>S</given-names></name><name><surname>Lopez de Castilla</surname><given-names>D</given-names></name><name><surname>Finberg</surname><given-names>RW</given-names></name><name><surname>Dierberg</surname><given-names>K</given-names></name><name><surname>Tapson</surname><given-names>V</given-names></name><name><surname>Hsieh</surname><given-names>L</given-names></name><name><surname>Patterson</surname><given-names>TF</given-names></name><name><surname>Paredes</surname><given-names>R</given-names></name><name><surname>Sweeney</surname><given-names>DA</given-names></name><name><surname>Short</surname><given-names>WR</given-names></name><name><surname>Touloumi</surname><given-names>G</given-names></name><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>Ohmagari</surname><given-names>N</given-names></name><name><surname>Oh</surname><given-names>M-D</given-names></name><name><surname>Ruiz-Palacios</surname><given-names>GM</given-names></name><name><surname>Benfield</surname><given-names>T</given-names></name><name><surname>Fätkenheuer</surname><given-names>G</given-names></name><name><surname>Kortepeter</surname><given-names>MG</given-names></name><name><surname>Atmar</surname><given-names>RL</given-names></name><name><surname>Creech</surname><given-names>CB</given-names></name><name><surname>Lundgren</surname><given-names>J</given-names></name><name><surname>Babiker</surname><given-names>AG</given-names></name><name><surname>Pett</surname><given-names>S</given-names></name><name><surname>Neaton</surname><given-names>JD</given-names></name><name><surname>Burgess</surname><given-names>TH</given-names></name><name><surname>Bonnett</surname><given-names>T</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Makowski</surname><given-names>M</given-names></name><name><surname>Osinusi</surname><given-names>A</given-names></name><name><surname>Nayak</surname><given-names>S</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><collab>ACTT-1 Study Group Members</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Remdesivir for the treatment of Covid-19-final report</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>1813</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2007764</pub-id><pub-id pub-id-type="pmid">32445440</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavez-MacGregor</surname><given-names>M</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Scheet</surname><given-names>P</given-names></name><name><surname>Giordano</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer</article-title><source>JAMA Oncology</source><volume>8</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2021.5148</pub-id><pub-id pub-id-type="pmid">34709356</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>RL</given-names></name><name><surname>Vaca</surname><given-names>CE</given-names></name><name><surname>Paredes</surname><given-names>R</given-names></name><name><surname>Mera</surname><given-names>J</given-names></name><name><surname>Webb</surname><given-names>BJ</given-names></name><name><surname>Perez</surname><given-names>G</given-names></name><name><surname>Oguchi</surname><given-names>G</given-names></name><name><surname>Ryan</surname><given-names>P</given-names></name><name><surname>Nielsen</surname><given-names>BU</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Hidalgo</surname><given-names>A</given-names></name><name><surname>Sachdeva</surname><given-names>Y</given-names></name><name><surname>Mittal</surname><given-names>S</given-names></name><name><surname>Osiyemi</surname><given-names>O</given-names></name><name><surname>Skarbinski</surname><given-names>J</given-names></name><name><surname>Juneja</surname><given-names>K</given-names></name><name><surname>Hyland</surname><given-names>RH</given-names></name><name><surname>Osinusi</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Camus</surname><given-names>G</given-names></name><name><surname>Abdelghany</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>S</given-names></name><name><surname>Behenna-Renton</surname><given-names>N</given-names></name><name><surname>Duff</surname><given-names>F</given-names></name><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Katz</surname><given-names>MJ</given-names></name><name><surname>Ginde</surname><given-names>AA</given-names></name><name><surname>Brown</surname><given-names>SM</given-names></name><name><surname>Schiffer</surname><given-names>JT</given-names></name><name><surname>Hill</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Early remdesivir to prevent progression to severe Covid-19 in outpatients</article-title><source>New England Journal of Medicine</source><volume>386</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116846</pub-id><pub-id pub-id-type="pmid">34937145</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>G</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Gale</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 in persons with haematological cancers</article-title><source>Leukemia</source><volume>34</volume><fpage>1637</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-0836-7</pub-id><pub-id pub-id-type="pmid">32332856</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horby</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Emberson</surname><given-names>JR</given-names></name><name><surname>Mafham</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>JL</given-names></name><name><surname>Linsell</surname><given-names>L</given-names></name><name><surname>Staplin</surname><given-names>N</given-names></name><name><surname>Brightling</surname><given-names>C</given-names></name><name><surname>Ustianowski</surname><given-names>A</given-names></name><name><surname>Elmahi</surname><given-names>E</given-names></name><name><surname>Prudon</surname><given-names>B</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Felton</surname><given-names>T</given-names></name><name><surname>Chadwick</surname><given-names>D</given-names></name><name><surname>Rege</surname><given-names>K</given-names></name><name><surname>Fegan</surname><given-names>C</given-names></name><name><surname>Chappell</surname><given-names>LC</given-names></name><name><surname>Faust</surname><given-names>SN</given-names></name><name><surname>Jaki</surname><given-names>T</given-names></name><name><surname>Jeffery</surname><given-names>K</given-names></name><name><surname>Montgomery</surname><given-names>A</given-names></name><name><surname>Rowan</surname><given-names>K</given-names></name><name><surname>Juszczak</surname><given-names>E</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Haynes</surname><given-names>R</given-names></name><name><surname>Landray</surname><given-names>MJ</given-names></name><collab>RECOVERY Collaborative Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Dexamethasone in hospitalized patients with covid-19</article-title><source>The New England Journal of Medicine</source><volume>384</volume><fpage>693</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id><pub-id pub-id-type="pmid">32678530</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janiaud</surname><given-names>P</given-names></name><name><surname>Axfors</surname><given-names>C</given-names></name><name><surname>Schmitt</surname><given-names>AM</given-names></name><name><surname>Gloy</surname><given-names>V</given-names></name><name><surname>Ebrahimi</surname><given-names>F</given-names></name><name><surname>Hepprich</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>ER</given-names></name><name><surname>Haber</surname><given-names>NA</given-names></name><name><surname>Khanna</surname><given-names>N</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Goodman</surname><given-names>SN</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name><name><surname>Hemkens</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis</article-title><source>JAMA</source><volume>325</volume><fpage>1185</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.2747</pub-id><pub-id pub-id-type="pmid">33635310</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Johns Hopkins Coronavirus Resource Center</collab></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 Map</article-title><ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</ext-link><date-in-citation iso-8601-date="2021-04-29">April 29, 2021</date-in-citation></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucirka</surname><given-names>LM</given-names></name><name><surname>Lauer</surname><given-names>SA</given-names></name><name><surname>Laeyendecker</surname><given-names>O</given-names></name><name><surname>Boon</surname><given-names>D</given-names></name><name><surname>Lessler</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-cov-2 tests by time since exposure</article-title><source>Annals of Internal Medicine</source><volume>173</volume><fpage>262</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.7326/M20-1495</pub-id><pub-id pub-id-type="pmid">32422057</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuderer</surname><given-names>NM</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Shah</surname><given-names>DP</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><name><surname>Rubinstein</surname><given-names>SM</given-names></name><name><surname>Rivera</surname><given-names>DR</given-names></name><name><surname>Shete</surname><given-names>S</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Desai</surname><given-names>A</given-names></name><name><surname>de Lima Lopes</surname><given-names>G</given-names></name><name><surname>Grivas</surname><given-names>P</given-names></name><name><surname>Painter</surname><given-names>CA</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>MA</given-names></name><name><surname>Bakouny</surname><given-names>Z</given-names></name><name><surname>Batist</surname><given-names>G</given-names></name><name><surname>Bekaii-Saab</surname><given-names>T</given-names></name><name><surname>Bilen</surname><given-names>MA</given-names></name><name><surname>Bouganim</surname><given-names>N</given-names></name><name><surname>Larroya</surname><given-names>MB</given-names></name><name><surname>Castellano</surname><given-names>D</given-names></name><name><surname>Del Prete</surname><given-names>SA</given-names></name><name><surname>Doroshow</surname><given-names>DB</given-names></name><name><surname>Egan</surname><given-names>PC</given-names></name><name><surname>Elkrief</surname><given-names>A</given-names></name><name><surname>Farmakiotis</surname><given-names>D</given-names></name><name><surname>Flora</surname><given-names>D</given-names></name><name><surname>Galsky</surname><given-names>MD</given-names></name><name><surname>Glover</surname><given-names>MJ</given-names></name><name><surname>Griffiths</surname><given-names>EA</given-names></name><name><surname>Gulati</surname><given-names>AP</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Hafez</surname><given-names>N</given-names></name><name><surname>Halfdanarson</surname><given-names>TR</given-names></name><name><surname>Hawley</surname><given-names>JE</given-names></name><name><surname>Hsu</surname><given-names>E</given-names></name><name><surname>Kasi</surname><given-names>A</given-names></name><name><surname>Khaki</surname><given-names>AR</given-names></name><name><surname>Lemmon</surname><given-names>CA</given-names></name><name><surname>Lewis</surname><given-names>C</given-names></name><name><surname>Logan</surname><given-names>B</given-names></name><name><surname>Masters</surname><given-names>T</given-names></name><name><surname>McKay</surname><given-names>RR</given-names></name><name><surname>Mesa</surname><given-names>RA</given-names></name><name><surname>Morgans</surname><given-names>AK</given-names></name><name><surname>Mulcahy</surname><given-names>MF</given-names></name><name><surname>Panagiotou</surname><given-names>OA</given-names></name><name><surname>Peddi</surname><given-names>P</given-names></name><name><surname>Pennell</surname><given-names>NA</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>Rosen</surname><given-names>LR</given-names></name><name><surname>Rosovsky</surname><given-names>R</given-names></name><name><surname>Salazar</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>SA</given-names></name><name><surname>Shaya</surname><given-names>JA</given-names></name><name><surname>Steinharter</surname><given-names>J</given-names></name><name><surname>Stockerl-Goldstein</surname><given-names>KE</given-names></name><name><surname>Subbiah</surname><given-names>S</given-names></name><name><surname>Vinh</surname><given-names>DC</given-names></name><name><surname>Wehbe</surname><given-names>FH</given-names></name><name><surname>Weissmann</surname><given-names>LB</given-names></name><name><surname>Wu</surname><given-names>JTY</given-names></name><name><surname>Wulff-Burchfield</surname><given-names>E</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Yeh</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>PP</given-names></name><name><surname>Zhou</surname><given-names>AY</given-names></name><name><surname>Zubiri</surname><given-names>L</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Lyman</surname><given-names>GH</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Warner</surname><given-names>JL</given-names></name><collab>COVID-19 and Cancer Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study</article-title><source>Lancet</source><volume>395</volume><fpage>1907</fpage><lpage>1918</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31187-9</pub-id><pub-id pub-id-type="pmid">32473681</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>KH</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>76</volume><fpage>1962</fpage><lpage>1968</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab093</pub-id><pub-id pub-id-type="pmid">33758946</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>LY</given-names></name><name><surname>Cazier</surname><given-names>JB</given-names></name><name><surname>Angelis</surname><given-names>V</given-names></name><name><surname>Arnold</surname><given-names>R</given-names></name><name><surname>Bisht</surname><given-names>V</given-names></name><name><surname>Campton</surname><given-names>NA</given-names></name><name><surname>Chackathayil</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>VW</given-names></name><name><surname>Curley</surname><given-names>HM</given-names></name><name><surname>Fittall</surname><given-names>MW</given-names></name><name><surname>Freeman-Mills</surname><given-names>L</given-names></name><name><surname>Gennatas</surname><given-names>S</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Hartley</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>DJ</given-names></name><name><surname>Kerr</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>RJ</given-names></name><name><surname>McGrath</surname><given-names>SE</given-names></name><name><surname>Middleton</surname><given-names>CP</given-names></name><name><surname>Murugaesu</surname><given-names>N</given-names></name><name><surname>Newsom-Davis</surname><given-names>T</given-names></name><name><surname>Okines</surname><given-names>AF</given-names></name><name><surname>Olsson-Brown</surname><given-names>AC</given-names></name><name><surname>Palles</surname><given-names>C</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Pettengell</surname><given-names>R</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Protheroe</surname><given-names>EA</given-names></name><name><surname>Purshouse</surname><given-names>K</given-names></name><name><surname>Sharma-Oates</surname><given-names>A</given-names></name><name><surname>Sivakumar</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Starkey</surname><given-names>T</given-names></name><name><surname>Turnbull</surname><given-names>CD</given-names></name><name><surname>Várnai</surname><given-names>C</given-names></name><name><surname>Yousaf</surname><given-names>N</given-names></name><name><surname>Kerr</surname><given-names>R</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><collab>UK Coronavirus Monitoring Project Team</collab></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study</article-title><source>Lancet</source><volume>395</volume><fpage>1919</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31173-9</pub-id><pub-id pub-id-type="pmid">32473682</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libster</surname><given-names>R</given-names></name><name><surname>Pérez Marc</surname><given-names>G</given-names></name><name><surname>Wappner</surname><given-names>D</given-names></name><name><surname>Coviello</surname><given-names>S</given-names></name><name><surname>Bianchi</surname><given-names>A</given-names></name><name><surname>Braem</surname><given-names>V</given-names></name><name><surname>Esteban</surname><given-names>I</given-names></name><name><surname>Caballero</surname><given-names>MT</given-names></name><name><surname>Wood</surname><given-names>C</given-names></name><name><surname>Berrueta</surname><given-names>M</given-names></name><name><surname>Rondan</surname><given-names>A</given-names></name><name><surname>Lescano</surname><given-names>G</given-names></name><name><surname>Cruz</surname><given-names>P</given-names></name><name><surname>Ritou</surname><given-names>Y</given-names></name><name><surname>Fernández Viña</surname><given-names>V</given-names></name><name><surname>Álvarez Paggi</surname><given-names>D</given-names></name><name><surname>Esperante</surname><given-names>S</given-names></name><name><surname>Ferreti</surname><given-names>A</given-names></name><name><surname>Ofman</surname><given-names>G</given-names></name><name><surname>Ciganda</surname><given-names>Á</given-names></name><name><surname>Rodriguez</surname><given-names>R</given-names></name><name><surname>Lantos</surname><given-names>J</given-names></name><name><surname>Valentini</surname><given-names>R</given-names></name><name><surname>Itcovici</surname><given-names>N</given-names></name><name><surname>Hintze</surname><given-names>A</given-names></name><name><surname>Oyarvide</surname><given-names>ML</given-names></name><name><surname>Etchegaray</surname><given-names>C</given-names></name><name><surname>Neira</surname><given-names>A</given-names></name><name><surname>Name</surname><given-names>I</given-names></name><name><surname>Alfonso</surname><given-names>J</given-names></name><name><surname>López Castelo</surname><given-names>R</given-names></name><name><surname>Caruso</surname><given-names>G</given-names></name><name><surname>Rapelius</surname><given-names>S</given-names></name><name><surname>Alvez</surname><given-names>F</given-names></name><name><surname>Etchenique</surname><given-names>F</given-names></name><name><surname>Dimase</surname><given-names>F</given-names></name><name><surname>Alvarez</surname><given-names>D</given-names></name><name><surname>Aranda</surname><given-names>SS</given-names></name><name><surname>Sánchez Yanotti</surname><given-names>C</given-names></name><name><surname>De Luca</surname><given-names>J</given-names></name><name><surname>Jares Baglivo</surname><given-names>S</given-names></name><name><surname>Laudanno</surname><given-names>S</given-names></name><name><surname>Nowogrodzki</surname><given-names>F</given-names></name><name><surname>Larrea</surname><given-names>R</given-names></name><name><surname>Silveyra</surname><given-names>M</given-names></name><name><surname>Leberzstein</surname><given-names>G</given-names></name><name><surname>Debonis</surname><given-names>A</given-names></name><name><surname>Molinos</surname><given-names>J</given-names></name><name><surname>González</surname><given-names>M</given-names></name><name><surname>Perez</surname><given-names>E</given-names></name><name><surname>Kreplak</surname><given-names>N</given-names></name><name><surname>Pastor Argüello</surname><given-names>S</given-names></name><name><surname>Gibbons</surname><given-names>L</given-names></name><name><surname>Althabe</surname><given-names>F</given-names></name><name><surname>Bergel</surname><given-names>E</given-names></name><name><surname>Polack</surname><given-names>FP</given-names></name><collab>Fundación INFANT–COVID-19 Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Early high-titer plasma therapy to prevent severe covid-19 in older adults</article-title><source>The New England Journal of Medicine</source><volume>384</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2033700</pub-id><pub-id pub-id-type="pmid">33406353</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunski</surname><given-names>MJ</given-names></name><name><surname>Burton</surname><given-names>J</given-names></name><name><surname>Tawagi</surname><given-names>K</given-names></name><name><surname>Maslov</surname><given-names>D</given-names></name><name><surname>Simenson</surname><given-names>V</given-names></name><name><surname>Barr</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Matrana</surname><given-names>M</given-names></name><name><surname>Cole</surname><given-names>J</given-names></name><name><surname>Larned</surname><given-names>Z</given-names></name><name><surname>Moore</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Multivariate mortality analyses in COVID-19: comparing patients with cancer and patients without cancer in Louisiana</article-title><source>Cancer</source><volume>127</volume><fpage>266</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1002/cncr.33243</pub-id><pub-id pub-id-type="pmid">33112411</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>V</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Kabarriti</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>D</given-names></name><name><surname>Goldfinger</surname><given-names>M</given-names></name><name><surname>Acuna-Villaorduna</surname><given-names>A</given-names></name><name><surname>Pradhan</surname><given-names>K</given-names></name><name><surname>Thota</surname><given-names>R</given-names></name><name><surname>Reissman</surname><given-names>S</given-names></name><name><surname>Sparano</surname><given-names>JA</given-names></name><name><surname>Gartrell</surname><given-names>BA</given-names></name><name><surname>Smith</surname><given-names>RV</given-names></name><name><surname>Ohri</surname><given-names>N</given-names></name><name><surname>Garg</surname><given-names>M</given-names></name><name><surname>Racine</surname><given-names>AD</given-names></name><name><surname>Kalnicki</surname><given-names>S</given-names></name><name><surname>Perez-Soler</surname><given-names>R</given-names></name><name><surname>Halmos</surname><given-names>B</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Case fatality rate of cancer patients with COVID-19 in a new York hospital system</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>935</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0516</pub-id><pub-id pub-id-type="pmid">32357994</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffari</surname><given-names>E</given-names></name><name><surname>Chandak</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Thrun</surname><given-names>M</given-names></name><name><surname>Gottlieb</surname><given-names>RL</given-names></name><name><surname>Kuritzkes</surname><given-names>DR</given-names></name><name><surname>Sax</surname><given-names>PE</given-names></name><name><surname>Wohl</surname><given-names>DA</given-names></name><name><surname>Casciano</surname><given-names>R</given-names></name><name><surname>Hodgkins</surname><given-names>P</given-names></name><name><surname>Haubrich</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort</article-title><source>Clinical Infectious Diseases</source><volume>75</volume><fpage>e450</fpage><lpage>e458</lpage><pub-id pub-id-type="doi">10.1093/cid/ciab875</pub-id><pub-id pub-id-type="pmid">34596223</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Henao-Restrepo</surname><given-names>AM</given-names></name><name><surname>Preziosi</surname><given-names>MP</given-names></name><name><surname>Sathiyamoorthy</surname><given-names>V</given-names></name><name><surname>Abdool Karim</surname><given-names>Q</given-names></name><name><surname>Alejandria</surname><given-names>MM</given-names></name><name><surname>Hernández García</surname><given-names>C</given-names></name><name><surname>Kieny</surname><given-names>MP</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>KS</given-names></name><name><surname>Roses Periago</surname><given-names>M</given-names></name><name><surname>Abi Hanna</surname><given-names>P</given-names></name><name><surname>Ader</surname><given-names>F</given-names></name><name><surname>Al-Bader</surname><given-names>AM</given-names></name><name><surname>Alhasawi</surname><given-names>A</given-names></name><name><surname>Allum</surname><given-names>E</given-names></name><name><surname>Alotaibi</surname><given-names>A</given-names></name><name><surname>Alvarez-Moreno</surname><given-names>CA</given-names></name><name><surname>Appadoo</surname><given-names>S</given-names></name><name><surname>Asiri</surname><given-names>A</given-names></name><name><surname>Aukrust</surname><given-names>P</given-names></name><name><surname>Barratt-Due</surname><given-names>A</given-names></name><name><surname>Bellani</surname><given-names>S</given-names></name><name><surname>Branca</surname><given-names>M</given-names></name><name><surname>Cappel-Porter</surname><given-names>HBC</given-names></name><name><surname>Cerrato</surname><given-names>N</given-names></name><name><surname>Chow</surname><given-names>TS</given-names></name><name><surname>Como</surname><given-names>N</given-names></name><name><surname>Eustace</surname><given-names>J</given-names></name><name><surname>García</surname><given-names>PJ</given-names></name><name><surname>Godbole</surname><given-names>S</given-names></name><name><surname>Gotuzzo</surname><given-names>E</given-names></name><name><surname>Griskevicius</surname><given-names>L</given-names></name><name><surname>Hamra</surname><given-names>R</given-names></name><name><surname>Hassan</surname><given-names>M</given-names></name><name><surname>Hassany</surname><given-names>M</given-names></name><name><surname>Hutton</surname><given-names>D</given-names></name><name><surname>Irmansyah</surname><given-names>I</given-names></name><name><surname>Jancoriene</surname><given-names>L</given-names></name><name><surname>Kirwan</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Lennon</surname><given-names>P</given-names></name><name><surname>Lopardo</surname><given-names>G</given-names></name><name><surname>Lydon</surname><given-names>P</given-names></name><name><surname>Magrini</surname><given-names>N</given-names></name><name><surname>Maguire</surname><given-names>T</given-names></name><name><surname>Manevska</surname><given-names>S</given-names></name><name><surname>Manuel</surname><given-names>O</given-names></name><name><surname>McGinty</surname><given-names>S</given-names></name><name><surname>Medina</surname><given-names>MT</given-names></name><name><surname>Mesa Rubio</surname><given-names>ML</given-names></name><name><surname>Miranda-Montoya</surname><given-names>MC</given-names></name><name><surname>Nel</surname><given-names>J</given-names></name><name><surname>Nunes</surname><given-names>EP</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Portolés</surname><given-names>A</given-names></name><name><surname>Rasmin</surname><given-names>MR</given-names></name><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Rees</surname><given-names>H</given-names></name><name><surname>Reges</surname><given-names>PPS</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><name><surname>Salami</surname><given-names>K</given-names></name><name><surname>Salvadori</surname><given-names>MI</given-names></name><name><surname>Sinani</surname><given-names>N</given-names></name><name><surname>Sterne</surname><given-names>JAC</given-names></name><name><surname>Stevanovikj</surname><given-names>M</given-names></name><name><surname>Tacconelli</surname><given-names>E</given-names></name><name><surname>Tikkinen</surname><given-names>KAO</given-names></name><name><surname>Trelle</surname><given-names>S</given-names></name><name><surname>Zaid</surname><given-names>H</given-names></name><name><surname>Røttingen</surname><given-names>JA</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><collab>WHO Solidarity Trial Consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Repurposed antiviral drugs for covid-19-interim who solidarity trial results</article-title><source>The New England Journal of Medicine</source><volume>384</volume><fpage>497</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2023184</pub-id><pub-id pub-id-type="pmid">33264556</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinato</surname><given-names>DJ</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Scotti</surname><given-names>L</given-names></name><name><surname>Colomba</surname><given-names>E</given-names></name><name><surname>Dolly</surname><given-names>S</given-names></name><name><surname>Loizidou</surname><given-names>A</given-names></name><name><surname>Chester</surname><given-names>J</given-names></name><name><surname>Mukherjee</surname><given-names>U</given-names></name><name><surname>Zambelli</surname><given-names>A</given-names></name><name><surname>Dalla Pria</surname><given-names>A</given-names></name><name><surname>Aguilar-Company</surname><given-names>J</given-names></name><name><surname>Bower</surname><given-names>M</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Bertuzzi</surname><given-names>A</given-names></name><name><surname>Brunet</surname><given-names>J</given-names></name><name><surname>Lambertini</surname><given-names>M</given-names></name><name><surname>Tagliamento</surname><given-names>M</given-names></name><name><surname>Pous</surname><given-names>A</given-names></name><name><surname>Sita-Lumsden</surname><given-names>A</given-names></name><name><surname>Srikandarajah</surname><given-names>K</given-names></name><name><surname>Colomba</surname><given-names>J</given-names></name><name><surname>Pommeret</surname><given-names>F</given-names></name><name><surname>Seguí</surname><given-names>E</given-names></name><name><surname>Generali</surname><given-names>D</given-names></name><name><surname>Grisanti</surname><given-names>S</given-names></name><name><surname>Pedrazzoli</surname><given-names>P</given-names></name><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Libertini</surname><given-names>M</given-names></name><name><surname>Moss</surname><given-names>C</given-names></name><name><surname>Evans</surname><given-names>JS</given-names></name><name><surname>Russell</surname><given-names>B</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name><name><surname>Vincenzi</surname><given-names>B</given-names></name><name><surname>Biello</surname><given-names>F</given-names></name><name><surname>Bertulli</surname><given-names>R</given-names></name><name><surname>Ottaviani</surname><given-names>D</given-names></name><name><surname>Liñan</surname><given-names>R</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Carmona-García</surname><given-names>MC</given-names></name><name><surname>Tondini</surname><given-names>C</given-names></name><name><surname>Fox</surname><given-names>L</given-names></name><name><surname>Baggi</surname><given-names>A</given-names></name><name><surname>Fotia</surname><given-names>V</given-names></name><name><surname>Parisi</surname><given-names>A</given-names></name><name><surname>Porzio</surname><given-names>G</given-names></name><name><surname>Queirolo</surname><given-names>P</given-names></name><name><surname>Cruz</surname><given-names>CA</given-names></name><name><surname>Saoudi-Gonzalez</surname><given-names>N</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Roqué Lloveras</surname><given-names>A</given-names></name><name><surname>Newsom-Davis</surname><given-names>T</given-names></name><name><surname>Sharkey</surname><given-names>R</given-names></name><name><surname>Roldán</surname><given-names>E</given-names></name><name><surname>Reyes</surname><given-names>R</given-names></name><name><surname>Zoratto</surname><given-names>F</given-names></name><name><surname>Earnshaw</surname><given-names>I</given-names></name><name><surname>Ferrante</surname><given-names>D</given-names></name><name><surname>Marco-Hernández</surname><given-names>J</given-names></name><name><surname>Ruiz-Camps</surname><given-names>I</given-names></name><name><surname>Gaidano</surname><given-names>G</given-names></name><name><surname>Patriarca</surname><given-names>A</given-names></name><name><surname>Bruna</surname><given-names>R</given-names></name><name><surname>Sureda</surname><given-names>A</given-names></name><name><surname>Martinez-Vila</surname><given-names>C</given-names></name><name><surname>Sanchez de Torre</surname><given-names>A</given-names></name><name><surname>Berardi</surname><given-names>R</given-names></name><name><surname>Giusti</surname><given-names>R</given-names></name><name><surname>Mazzoni</surname><given-names>F</given-names></name><name><surname>Guida</surname><given-names>A</given-names></name><name><surname>Rimassa</surname><given-names>L</given-names></name><name><surname>Chiudinelli</surname><given-names>L</given-names></name><name><surname>Franchi</surname><given-names>M</given-names></name><name><surname>Krengli</surname><given-names>M</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Prat</surname><given-names>A</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Van Hemelrijck</surname><given-names>M</given-names></name><name><surname>Diamantis</surname><given-names>N</given-names></name><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>Cortellini</surname><given-names>A</given-names></name><collab>OnCovid Study Group</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Time-dependent COVID-19 mortality in patients with cancer: an updated analysis of the oncovid registry</article-title><source>JAMA Oncology</source><volume>8</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2021.6199</pub-id><pub-id pub-id-type="pmid">34817562</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezagholizadeh</surname><given-names>A</given-names></name><name><surname>Khiali</surname><given-names>S</given-names></name><name><surname>Sarbakhsh</surname><given-names>P</given-names></name><name><surname>Entezari-Maleki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis</article-title><source>European Journal of Pharmacology</source><volume>897</volume><elocation-id>173926</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejphar.2021.173926</pub-id><pub-id pub-id-type="pmid">33549577</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>DR</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>Panagiotou</surname><given-names>OA</given-names></name><name><surname>Shah</surname><given-names>DP</given-names></name><name><surname>Kuderer</surname><given-names>NM</given-names></name><name><surname>Hsu</surname><given-names>C-Y</given-names></name><name><surname>Rubinstein</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>BJ</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>de Lima Lopes</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Grivas</surname><given-names>P</given-names></name><name><surname>Painter</surname><given-names>CA</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Thompson</surname><given-names>MA</given-names></name><name><surname>Arcobello</surname><given-names>J</given-names></name><name><surname>Bakouny</surname><given-names>Z</given-names></name><name><surname>Doroshow</surname><given-names>DB</given-names></name><name><surname>Egan</surname><given-names>PC</given-names></name><name><surname>Farmakiotis</surname><given-names>D</given-names></name><name><surname>Fecher</surname><given-names>LA</given-names></name><name><surname>Friese</surname><given-names>CR</given-names></name><name><surname>Galsky</surname><given-names>MD</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Halfdanarson</surname><given-names>TR</given-names></name><name><surname>Halmos</surname><given-names>B</given-names></name><name><surname>Hawley</surname><given-names>JE</given-names></name><name><surname>Khaki</surname><given-names>AR</given-names></name><name><surname>Lemmon</surname><given-names>CA</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Olszewski</surname><given-names>AJ</given-names></name><name><surname>Pennell</surname><given-names>NA</given-names></name><name><surname>Puc</surname><given-names>MM</given-names></name><name><surname>Revankar</surname><given-names>SG</given-names></name><name><surname>Schapira</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>Shah</surname><given-names>SA</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Yeh</surname><given-names>AC</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><name><surname>Lyman</surname><given-names>GH</given-names></name><name><surname>Warner</surname><given-names>JL</given-names></name><collab>COVID-19 and Cancer Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer Consortium (CCC19) cohort study</article-title><source>Cancer Discovery</source><volume>10</volume><fpage>1514</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0941</pub-id><pub-id pub-id-type="pmid">32699031</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robilotti</surname><given-names>EV</given-names></name><name><surname>Babady</surname><given-names>NE</given-names></name><name><surname>Mead</surname><given-names>PA</given-names></name><name><surname>Rolling</surname><given-names>T</given-names></name><name><surname>Perez-Johnston</surname><given-names>R</given-names></name><name><surname>Bernardes</surname><given-names>M</given-names></name><name><surname>Bogler</surname><given-names>Y</given-names></name><name><surname>Caldararo</surname><given-names>M</given-names></name><name><surname>Figueroa</surname><given-names>CJ</given-names></name><name><surname>Glickman</surname><given-names>MS</given-names></name><name><surname>Joanow</surname><given-names>A</given-names></name><name><surname>Kaltsas</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Lucca</surname><given-names>A</given-names></name><name><surname>Mariano</surname><given-names>A</given-names></name><name><surname>Morjaria</surname><given-names>S</given-names></name><name><surname>Nawar</surname><given-names>T</given-names></name><name><surname>Papanicolaou</surname><given-names>GA</given-names></name><name><surname>Predmore</surname><given-names>J</given-names></name><name><surname>Redelman-Sidi</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Seo</surname><given-names>SK</given-names></name><name><surname>Sepkowitz</surname><given-names>K</given-names></name><name><surname>Shah</surname><given-names>MK</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hohl</surname><given-names>TM</given-names></name><name><surname>Taur</surname><given-names>Y</given-names></name><name><surname>Kamboj</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Determinants of COVID-19 disease severity in patients with cancer</article-title><source>Nature Medicine</source><volume>26</volume><fpage>1218</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0979-0</pub-id><pub-id pub-id-type="pmid">32581323</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rüthrich</surname><given-names>MM</given-names></name><name><surname>Giessen-Jung</surname><given-names>C</given-names></name><name><surname>Borgmann</surname><given-names>S</given-names></name><name><surname>Classen</surname><given-names>AY</given-names></name><name><surname>Dolff</surname><given-names>S</given-names></name><name><surname>Grüner</surname><given-names>B</given-names></name><name><surname>Hanses</surname><given-names>F</given-names></name><name><surname>Isberner</surname><given-names>N</given-names></name><name><surname>Köhler</surname><given-names>P</given-names></name><name><surname>Lanznaster</surname><given-names>J</given-names></name><name><surname>Merle</surname><given-names>U</given-names></name><name><surname>Nadalin</surname><given-names>S</given-names></name><name><surname>Piepel</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Schons</surname><given-names>M</given-names></name><name><surname>Strauss</surname><given-names>R</given-names></name><name><surname>Tometten</surname><given-names>L</given-names></name><name><surname>Vehreschild</surname><given-names>JJ</given-names></name><name><surname>von Lilienfeld-Toal</surname><given-names>M</given-names></name><name><surname>Beutel</surname><given-names>G</given-names></name><name><surname>Wille</surname><given-names>K</given-names></name><collab>LEOSS Study Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry</article-title><source>Annals of Hematology</source><volume>100</volume><fpage>383</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1007/s00277-020-04328-4</pub-id><pub-id pub-id-type="pmid">33159569</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>E</given-names></name><name><surname>Christensen</surname><given-names>PA</given-names></name><name><surname>Graviss</surname><given-names>EA</given-names></name><name><surname>Nguyen</surname><given-names>DT</given-names></name><name><surname>Castillo</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lopez</surname><given-names>BV</given-names></name><name><surname>Eagar</surname><given-names>TN</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Shehabeldin</surname><given-names>A</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Masud</surname><given-names>F</given-names></name><name><surname>Leveque</surname><given-names>C</given-names></name><name><surname>Olsen</surname><given-names>RJ</given-names></name><name><surname>Bernard</surname><given-names>DW</given-names></name><name><surname>Gollihar</surname><given-names>J</given-names></name><name><surname>Musser</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-cov-2) spike protein IgG</article-title><source>The American Journal of Pathology</source><volume>191</volume><fpage>90</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2020.10.008</pub-id><pub-id pub-id-type="pmid">33157066</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AL</given-names></name><name><surname>Labaki</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>C-Y</given-names></name><name><surname>Bakouny</surname><given-names>Z</given-names></name><name><surname>Balanchivadze</surname><given-names>N</given-names></name><name><surname>Berg</surname><given-names>SA</given-names></name><name><surname>Blau</surname><given-names>S</given-names></name><name><surname>Daher</surname><given-names>A</given-names></name><name><surname>El Zarif</surname><given-names>T</given-names></name><name><surname>Friese</surname><given-names>CR</given-names></name><name><surname>Griffiths</surname><given-names>EA</given-names></name><name><surname>Hawley</surname><given-names>JE</given-names></name><name><surname>Hayes-Lattin</surname><given-names>B</given-names></name><name><surname>Karivedu</surname><given-names>V</given-names></name><name><surname>Latif</surname><given-names>T</given-names></name><name><surname>Mavromatis</surname><given-names>BH</given-names></name><name><surname>McKay</surname><given-names>RR</given-names></name><name><surname>Nagaraj</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>RH</given-names></name><name><surname>Panagiotou</surname><given-names>OA</given-names></name><name><surname>Portuguese</surname><given-names>AJ</given-names></name><name><surname>Puc</surname><given-names>M</given-names></name><name><surname>Santos Dutra</surname><given-names>M</given-names></name><name><surname>Schroeder</surname><given-names>BA</given-names></name><name><surname>Thakkar</surname><given-names>A</given-names></name><name><surname>Wulff-Burchfield</surname><given-names>EM</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Farmakiotis</surname><given-names>D</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><name><surname>Warner</surname><given-names>JL</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><collab>COVID-19 and Cancer Consortium</collab></person-group><year iso-8601-date="2022">2022</year><article-title>COVID-19 vaccination and breakthrough infections in patients with cancer</article-title><source>Annals of Oncology</source><volume>33</volume><fpage>340</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.12.006</pub-id><pub-id pub-id-type="pmid">34958894</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>DB</given-names></name><name><surname>Budhathoki</surname><given-names>P</given-names></name><name><surname>Syed</surname><given-names>NIH</given-names></name><name><surname>Rawal</surname><given-names>E</given-names></name><name><surname>Raut</surname><given-names>S</given-names></name><name><surname>Khadka</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Remdesivir: A potential game-changer or just A myth? A systematic review and meta-analysis</article-title><source>Life Sciences</source><volume>264</volume><elocation-id>118663</elocation-id><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118663</pub-id><pub-id pub-id-type="pmid">33121991</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>HK</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal</article-title><source>The Journal of Heart and Lung Transplantation</source><volume>39</volume><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2020.03.012</pub-id><pub-id pub-id-type="pmid">32362390</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siemieniuk</surname><given-names>RA</given-names></name><name><surname>Bartoszko</surname><given-names>JJ</given-names></name><name><surname>Zeraatkar</surname><given-names>D</given-names></name><name><surname>Kum</surname><given-names>E</given-names></name><name><surname>Qasim</surname><given-names>A</given-names></name><name><surname>Díaz Martinez</surname><given-names>JP</given-names></name><name><surname>Izcovich</surname><given-names>A</given-names></name><name><surname>Rochwerg</surname><given-names>B</given-names></name><name><surname>Lamontagne</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>MA</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Agoritsas</surname><given-names>T</given-names></name><name><surname>Azab</surname><given-names>M</given-names></name><name><surname>Bravo</surname><given-names>G</given-names></name><name><surname>Chu</surname><given-names>DK</given-names></name><name><surname>Couban</surname><given-names>R</given-names></name><name><surname>Cusano</surname><given-names>E</given-names></name><name><surname>Devji</surname><given-names>T</given-names></name><name><surname>Escamilla</surname><given-names>Z</given-names></name><name><surname>Foroutan</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Ghadimi</surname><given-names>M</given-names></name><name><surname>Heels-Ansdell</surname><given-names>D</given-names></name><name><surname>Honarmand</surname><given-names>K</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Ibrahim</surname><given-names>S</given-names></name><name><surname>Khamis</surname><given-names>A</given-names></name><name><surname>Lam</surname><given-names>B</given-names></name><name><surname>Mansilla</surname><given-names>C</given-names></name><name><surname>Loeb</surname><given-names>M</given-names></name><name><surname>Miroshnychenko</surname><given-names>A</given-names></name><name><surname>Marcucci</surname><given-names>M</given-names></name><name><surname>McLeod</surname><given-names>SL</given-names></name><name><surname>Motaghi</surname><given-names>S</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Mustafa</surname><given-names>RA</given-names></name><name><surname>Pardo-Hernandez</surname><given-names>H</given-names></name><name><surname>Rada</surname><given-names>G</given-names></name><name><surname>Rizwan</surname><given-names>Y</given-names></name><name><surname>Saadat</surname><given-names>P</given-names></name><name><surname>Switzer</surname><given-names>C</given-names></name><name><surname>Thabane</surname><given-names>L</given-names></name><name><surname>Tomlinson</surname><given-names>G</given-names></name><name><surname>Vandvik</surname><given-names>PO</given-names></name><name><surname>Vernooij</surname><given-names>RW</given-names></name><name><surname>Viteri-García</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Brignardello-Petersen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Drug treatments for covid-19: living systematic review and network meta-analysis</article-title><source>BMJ</source><volume>370</volume><elocation-id>m2980</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.m2980</pub-id><pub-id pub-id-type="pmid">32732190</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterne</surname><given-names>JAC</given-names></name><name><surname>Murthy</surname><given-names>S</given-names></name><name><surname>Diaz</surname><given-names>JV</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Azevedo</surname><given-names>LCP</given-names></name><name><surname>Berwanger</surname><given-names>O</given-names></name><name><surname>Cavalcanti</surname><given-names>AB</given-names></name><name><surname>Dequin</surname><given-names>PF</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>Emberson</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>D</given-names></name><name><surname>Giraudeau</surname><given-names>B</given-names></name><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Granholm</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>C</given-names></name><name><surname>Haynes</surname><given-names>R</given-names></name><name><surname>Heming</surname><given-names>N</given-names></name><name><surname>Higgins</surname><given-names>JPT</given-names></name><name><surname>Horby</surname><given-names>P</given-names></name><name><surname>Jüni</surname><given-names>P</given-names></name><name><surname>Landray</surname><given-names>MJ</given-names></name><name><surname>Le Gouge</surname><given-names>A</given-names></name><name><surname>Leclerc</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>WS</given-names></name><name><surname>Machado</surname><given-names>FR</given-names></name><name><surname>McArthur</surname><given-names>C</given-names></name><name><surname>Meziani</surname><given-names>F</given-names></name><name><surname>Møller</surname><given-names>MH</given-names></name><name><surname>Perner</surname><given-names>A</given-names></name><name><surname>Petersen</surname><given-names>MW</given-names></name><name><surname>Savovic</surname><given-names>J</given-names></name><name><surname>Tomazini</surname><given-names>B</given-names></name><name><surname>Veiga</surname><given-names>VC</given-names></name><name><surname>Webb</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><collab>WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis</article-title><source>JAMA</source><volume>324</volume><fpage>1330</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.17023</pub-id><pub-id pub-id-type="pmid">32876694</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Surya</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>AN</given-names></name><name><surname>Desai</surname><given-names>H</given-names></name><name><surname>Doucette</surname><given-names>A</given-names></name><name><surname>Gabriel</surname><given-names>P</given-names></name><name><surname>Ritchie</surname><given-names>M</given-names></name><name><surname>Rader</surname><given-names>D</given-names></name><name><surname>Maillard</surname><given-names>I</given-names></name><name><surname>Bange</surname><given-names>E</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>DeMichele</surname><given-names>A</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Mamtani</surname><given-names>R</given-names></name><name><surname>Maxwell</surname><given-names>KN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Rates of COVID-19-Related Outcomes in Cancer Compared to Non-Cancer Patients</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2020.08.14.20174961</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>X-P</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study</article-title><source>The Lancet. Oncology</source><volume>21</volume><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30309-0</pub-id><pub-id pub-id-type="pmid">32479790</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in wuhan, china: a retrospective cohort study</article-title><source>Lancet</source><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81127.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Turajlic</surname><given-names>Samra</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.25.22279181" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.25.22279181"/></front-stub><body><p>This study addresses the important subject of correlates of COVID-19 mortality in patients with cancer. It is a large multinational cohort of patients. The authors provide solid evidence based on careful multivariate analysis for the finding that cancer is not an independent risk factor for COVID-19 death.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81127.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Turajlic</surname><given-names>Samra</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Fendler</surname><given-names>Annika</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04tnbqb63</institution-id><institution>The Francis Crick Institute</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.25.22279181">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.08.25.22279181v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Eduardo Franco as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Annika Fendler (Reviewer #1).</p><p>As is customary in <italic>eLife</italic>, the reviewers have discussed their critiques with one another and with the editors. What follows below is our edited compilation of the essential and ancillary points provided by reviewers in their critiques and in their interaction post-review. Please submit a revised version that addresses these concerns directly. Although we expect that you will address these comments in your response letter, we also need to see the corresponding revision clearly marked in the text of the manuscript. Some of the reviewers' comments may seem to be simple queries or challenges that do not prompt revisions to the text. Please keep in mind, however, that readers may have the same perspective as the reviewers. Therefore, it is essential that you attempt to amend or expand the text to clarify the narrative accordingly.</p><p>Essential revisions:</p><p>(1) Consort diagram to explain attrition.</p><p>(2) Sensitivity analysis to evaluate the impact of data missingness.</p><p>(3) Justify clearly the choice of multivariate models.</p><p>4) Detail the cause of death as per reviewer 1.</p><p>(5) Discuss the fact this is an unvaccinated cohort and how that has implications in the context of vaccination.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>– The data contain a lot of missing values, likely due to the nature of data collection. The authors should perform a sensitivity analysis to explore how this affects their results.</p><p>– The authors mention that patients were lost to follow-up especially those not hospitalised. I'm not clear how many patients are in both groups. I also can't see how many patients were censored in the Kaplan-Meyer Analysis. A consort diagram would be helpful to understand how many patients the primary endpoint could be investigated.</p><p>– The authors present several multivariate models. It is not clear how they chose which data to include and on what basis the variables were selected.</p><p>– The authors describe that 348 patients died, and 93% of death are COVID-related. How was this split between patients with cancer and those without? Was there a difference in the proportion of death that was COVID-19-related?</p><p>– An overview of all treatments that patients received is missing. Were these similar between patients with cancer and those without? Did they differ by country? Did this impact outcome?</p><p>– The discussion is very long and includes a detailed description of published studies. The authors should summarise the findings of previously published studies in a concise way and restrict this discussion only to the direct results presented in the paper. For example, the authors discuss in length which treatment should be given at a certain stage of COVID-19, which is not directly relevant to the data they present.</p><p>– The authors only briefly discuss that this study was conducted in an unvaccinated cohort. They should include a more detailed discussion of and how their data apply to the current situation.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>Suggestions to the authors before considering this paper for publication:</p><p>(1) Replace the term &quot;cancer patients and non-cancer patients&quot; with &quot;patients with and without cancer&quot;.</p><p>(2) It is unclear what tables 2 and 3 add to the manuscript and the authors might want to consider moving them to the supplement.</p><p>(3) The table of patients at risk shown in Figure 1 should be adjusted to include data at some, but not all time points.</p><p>4) The authors may want to cite PMID: 34958894 to discuss the impact of cancer on patients with COVID-19 in the era of COVID-19 vaccines.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81127.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Consort diagram to explain attrition.</p></disp-quote><p>We have added a consort diagram to explain patient attrition as shown in figure 1.</p><disp-quote content-type="editor-comment"><p>2) Sensitivity analysis to evaluate the impact of data missingness.</p></disp-quote><p>We performed a sensitivity analysis to evaluate the impact of data missingness on our primary data analysis. Please see below the detailed response to the reviewer.</p><disp-quote content-type="editor-comment"><p>3) Justify clearly the choice of multivariate models.</p></disp-quote><p>We have provided a detailed description of the performance of our multivariable logistic regression analyses including variable selection, univariable analysis, multivariable analysis and the final models. Please see below the detailed response to the reviewer’s comment.</p><disp-quote content-type="editor-comment"><p>(4) Detail the cause of death as per reviewer 1.</p></disp-quote><p>We have revised the manuscript to reflect that any death that occurred within 30 days after COVID-19 diagnosis was considered to be COVID-related, irrespective of other comorbidities that could have contributed to death.</p><disp-quote content-type="editor-comment"><p>(5) Discuss the fact this is an unvaccinated cohort and how that has implications in the context of vaccination.</p></disp-quote><p>We agree with the reviewer and have acknowledged this limitation in the Discussion section as follows: “Last, this study was conducted prior to the introduction of COVID vaccines and included patients who were not vaccinated and who were infected by early variants which limits the generalizability of our results to contemporary COVID-19 patients”. We have added in the Discussion section the results of a recent study on the impact of vaccination in cancer patients.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>– The data contain a lot of missing values, likely due to the nature of data collection. The authors should perform a sensitivity analysis to explore how this affects their results.</p></disp-quote><p>We totally agree with the reviewer. This study aimed to identify risk factors for 30-day mortality of COVID-19 patients and the data had a lot of missing values. Following this advice, we performed a sensitivity analysis to evaluate the impact of missing data on our primary data analysis. We first estimated missing values using multiple imputation technique and then performed a multivariable analysis based on the imputed datasets. Lastly, the analysis results were compared between our initial primary analysis based on the complete cases (patients with no missing values for the variables retained for the final multivariable model) and the analysis based on the imputed datasets. We have added the sensitivity analyses results in the revised manuscript in Table 3 (for all patients) and Table 4 (for patients with (A) and without cancer (B)) and summarized the main findings in Results section. We also included a description of the sensitivity analysis in the revised Statistical analysis section.</p><disp-quote content-type="editor-comment"><p>– The authors mention that patients were lost to follow-up especially those not hospitalised. I'm not clear how many patients are in both groups. I also can't see how many patients were censored in the Kaplan-Meyer Analysis. A consort diagram would be helpful to understand how many patients the primary endpoint could be investigated.</p></disp-quote><p>We are sorry, we did not make a statement about loss to follow-up in the manuscript and there might be a misunderstanding about it. We mentioned “some non-cancer centers contributed data only on their hospitalized patients who were likely sicker” because some non-cancer centers provided only hospitalized (non-cancer) patients to this study. We considered it a study limitation in Discussion section because of a possible imbalance in COVID-19 infection severity between patients with and without cancer in our study population. Regarding loss to follow up, although our data had a lot of missing values for many variables, the data for the primary endpoint 30-day mortality were relatively complete, and there were only 10 patients excluded from the Kaplan-Meier analysis due to their missing death dates, including 8 patients with cancer and 2 patients without cancer. However, after redoing multivariable analysis adjusting for country as advised by another comment, we found that cancer was no longer independently associated with 30-day mortality. Therefore, the Kaplan-Meier showing a significant impact of cancer on mortality has been no longer appropriate for this manuscript and therefore, we have removed this figure form the revised manuscript. As advised, a consort diagram of patient attrition has been added to the manuscript (Please see Figure 1).</p><disp-quote content-type="editor-comment"><p>– The authors present several multivariate models. It is not clear how they chose which data to include and on what basis the variables were selected.</p></disp-quote><p>We thank the reviewer for this comment and have modified the Statistical Analysis section by providing a detailed description of the performance of our multivariable logistic regression analyses including variable selection, univariable analysis, multivariable analysis and the final models.</p><disp-quote content-type="editor-comment"><p>– The authors describe that 348 patients died, and 93% of death are COVID-related. How was this split between patients with cancer and those without? Was there a difference in the proportion of death that was COVID-19-related?</p></disp-quote><p>We have revised the manuscript to reflect that any death that occurred within 30 days after COVID-19 diagnosis was considered to be COVID-19-related, irrespective of other comorbidities that could have contributed to death. We have revised the manuscript accordingly.</p><disp-quote content-type="editor-comment"><p>– An overview of all treatments that patients received is missing. Were these similar between patients with cancer and those without? Did they differ by country? Did this impact outcome?</p></disp-quote><p>Treatment data are an important part of this study and we apologize for missing to provide them. We have added the treatment data in Table 1. As we can see, there was a significant difference in every treatment received between patients with and without cancer. Treatments that patients received also significantly differed by country and we have added this finding in Results section. In addition, to account for the treatment differences among the countries, we redid multivariable logistic regression analyses on mortality with adjusting for the country effect. Compared to our previous analysis, a main change in the new analyses is that cancer was no longer an independent risk factor for 30-day mortality after adjusting for country in multivariable analysis. We believe that lymphopenia and possibly anemia which occurred more frequently in cancer patients (Table 1) might be the confounding independent variables that made cancer appear to be associated with higher mortality by univariate analysis. Another change is that among patients without cancer, remdesivir was no longer independently associated with 30-day mortality, while it still had a similar significant impact on reducing mortality among all patients and among patients with cancer. We have updated the analyses results in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>– The discussion is very long and includes a detailed description of published studies. The authors should summarise the findings of previously published studies in a concise way and restrict this discussion only to the direct results presented in the paper. For example, the authors discuss in length which treatment should be given at a certain stage of COVID-19, which is not directly relevant to the data they present.</p><p>– The authors only briefly discuss that this study was conducted in an unvaccinated cohort. They should include a more detailed discussion of and how their data apply to the current situation.</p></disp-quote><p>We have shortened our discussion to mainly focus on our results. We agree with the reviewer that this study was conducted in an unvaccinated cohort before the introduction of COVID vaccines and have acknowledged this limitation in the Discussion section as follows: “Last, this study was conducted prior to the introduction of COVID vaccines and included patients who were not vaccinated and who were infected by early variants which limits the generalizability of our results to contemporary COVID-19 patients”. We have added in the Discussion section the results of a recent study on the impact of vaccination in cancer patients.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>Suggestions to the authors before considering this paper for publication:</p><p>(1) Replace the term &quot;cancer patients and non-cancer patients&quot; with &quot;patients with and without cancer&quot;.</p></disp-quote><p>We have replaced the term “cancer patients and non-cancer patients” with “patients with and without cancer” as requested throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>(2) It is unclear what tables 2 and 3 add to the manuscript and the authors might want to consider moving them to the supplement.</p></disp-quote><p>We thank the reviewer for their comments. We have shortened table 2 and moved table 3 to supplement Table 1. We have added additional tables and a new figure to address the other comments.</p><disp-quote content-type="editor-comment"><p>(3) The table of patients at risk shown in Figure 1 should be adjusted to include data at some, but not all time points.</p></disp-quote><p>We agree and thank the reviewer for the advice. However, after redoing multivariable analysis adjusting for country as advised in another comment, we found that cancer was no longer independently associated with 30-day mortality. Therefore, the Kaplan-Meier showing a significant impact of cancer on mortality has been no longer appropriate for this manuscript and therefore, we have removed this figure form the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(4) The authors may want to cite PMID: 34958894 to discuss the impact of cancer on patients with COVID-19 in the era of COVID-19 vaccines.</p></disp-quote><p>We have cited this reference and added the findings of the impact of vaccination in patients with cancer in the Discussion section.</p></body></sub-article></article>